

# Research Toward a Cure April 14, 2022

**Table 1. Current Clinical Trials**

| Trial   | Trial Registry Identifier(s)                                 | Sponsor(s)   | Phase     | Estimated End Date/Interim Results   |
|---|--|--|-----------|--|
| <b>ADOPTIVE IMMUNOTHERAPY</b>   |  |  |           |  |
| <b>AutoRESIST:</b> HIV antigen-specific T-cells targeting conserved epitopes for treatment of HIV-associated lymphoma   | <a href="#">NCT04975698</a>                                  | Catherine Bollard, Children's Research Institute                       | Phase II  | June 2026  |
| <b>AlloRESIST:</b> Evaluate the safety, immunologic, and virologic responses of donor derived HIV-specific T-cells in HIV+ individuals following allogeneic bone marrow transplantation | <a href="#">NCT04248192</a>                                  | Catherine Bollard, Children's Research Institute                       | Phase I   | April 2024   |
| <b>HST-NEETs:</b> HIV-1 specific T-cells for HIV+ individuals   | <a href="#">NCT03485963</a><br>(closed to enrollment)        | Children's Research Institute  | Phase I   | December 2023  |
| <b>ANTIBODIES</b>   |  |  |           |  |
| <b>VRC01</b> (analytical treatment interruption in HVTN 703/HPTN 081 AMP trial participants)  | <a href="#">NCT04860323</a>                                  | HIV Vaccine Trials Network   | N/A       | November 2022  |
| <b>VRC01</b> (analytical treatment interruption in HVTN 704/HPTN 085 AMP trial participants)  | <a href="#">NCT04801758</a>                                  | HIV Vaccine Trials Network   | N/A       | June 2023  |
| <b>GSK3810109A</b> (broadly neutralizing antibody formerly named N6-LS)   | <a href="#">NCT04871113</a>                                  | ViiV Healthcare  | Phase IIa | November 2023  |
| <b>10-1074-LS + 3BNC117-LS</b> in primary HIV infection   | <a href="#">NCT04319367</a>                                  | Imperial College London  | Phase II  | March 2025<br><a href="#">Trials. 2022 Apr 5;23(1):263</a>                               |
| <b>3BNC117-LS + 10-1074-LS</b>  | <a href="#">NCT05300035</a><br>(not yet open for enrollment) | French National Agency for Research on AIDS and Viral Hepatitis (ANRS) | Phase II  | February 2028  |
| <b>UB-421</b> (antibody inhibitor of HIV binding to CD4 receptors)  | <a href="#">NCT04404049</a><br>(not yet open for enrollment) | UBP Greater China (Shanghai) Co., Ltd                                  | Phase II  | June 2024  |
| <b>UB-421</b>   | <a href="#">NCT03743376</a><br>(closed to enrollment)        | United BioPharma   | Phase II  | December 2021  |
| <b>vedolizumab</b> (anti- $\alpha_4\beta_7$ integrin antibody)  | <a href="#">NCT03147859</a>                                  | Ottawa Hospital Research Institute                                     | Phase II  | December 2021<br>CROI 2019,<br><a href="#">Abstract 393</a> ,<br><a href="#">Webcast</a> |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure April 14, 2022

**Table 1. Current Clinical Trials (Cont.)**

| Trial  | Trial Registry Identifier(s)                                 | Manufacturer/<br>Sponsor(s)             | Phase       | Estimated End<br>Date/Interim<br>Results  |
|--|--|---|-------------|---|
| <b>ANTIBODIES (Cont.)</b>  |  |   |             |   |
| <b>PGT121 + VRC07-523LS +/- PGDM1400</b> (broadly neutralizing antibodies) | <a href="#">NCT03721510</a>                                  | International AIDS Vaccine Initiative   | Phase I/IIa | October 2022  |
| <b>ABBV-382</b> (anti- $\alpha_4\beta_7$ integrin antibody)                | <a href="#">NCT04554966</a>                                  | AbbVie                                  | Phase Ib    | February 2023   |
| <b>3BNC117-LS + 10-1074-LS</b>   | <a href="#">NCT05079451</a><br>(not yet open for enrollment) | NIAID                                   | Phase I     | February 2024   |
| <b>AAV8-VRC07</b> (broadly neutralizing antibody delivered by AAV vector)  | <a href="#">NCT03374202</a><br>(closed to enrollment)        | NIAID                                   | Phase I     | March 2027<br><a href="#">Nat Med. 2022 Apr 11</a><br>CROI 2022,<br><a href="#">Abstract 498</a><br>CROI 2021,<br><a href="#">Abstract 160</a> ,<br><a href="#">Webcast</a><br>CROI 2020,<br><a href="#">Abstract 41LB</a> ,<br><a href="#">Webcast</a> |
| <b>SAR441236</b> (tri-specific broadly neutralizing antibody)              | <a href="#">NCT03705169</a>                                  | NIAID                                   | Phase I     | November 2022   |
| <b>ANTI-CMV THERAPY</b>  |  |   |             |   |
| <b>Ietermovir</b> (Prevymsis)  | <a href="#">NCT04840199</a><br>(not yet open for enrollment) | NIAID                                   | Phase II    | June 2024   |
| <b>ANTI-INFLAMMATORY</b>   |  |   |             |   |
| <b>canakinumab</b> (IL-1 $\beta$ inhibitor)                                | <a href="#">NCT02272946</a><br>(closed to enrollment)        | University of California, San Francisco | Phase II    | December 2022<br><a href="#">J Am Coll Cardiol. 2018;72(22):2809-2811.</a><br>CROI 2017,<br><a href="#">Abstract 126</a> ,<br><a href="#">Webcast</a>   |
| <b>Camu Camu</b> ( <i>Myrciaria dubia</i> )                                | <a href="#">NCT04058392</a>                                  | McGill University Health Centre         | Phase I     | December 2022   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure April 14, 2022

Table 1. Current Clinical Trials (Cont.)

| Trial   | Trial Registry Identifier(s)                                 | Manufacturer/<br>Sponsor(s)            | Phase      | Estimated End Date/Interim Results |
|---|--|--|------------|------------------------------------|
| <b>ANTIRETROVIRAL THERAPY</b>   |  |  |            |                                    |
| <b>IDOLTIB:</b> Impact of dolutegravir + lamivudine simplification on HIV-1 reservoirs  | <a href="#">NCT04034862</a>                                  | University of Liege                    | Phase III  | March 2022                         |
| <b>CANNABINOIDS</b>   |  |  |            |                                    |
| <b>GALIG-CBD:</b> Effects of cannabidiol on the activation of autophagy and inflammation genes, functional consequences in virologically controlled HIV+ patients | <a href="#">NCT05306249</a><br>(not yet open for enrollment) | Centre Hospitalier Régional d'Orléans  | Phase II   | November 2022                      |
| <b>TN-CT11LM, TN-TC19LM</b> oral capsules   | <a href="#">NCT03550352</a><br>(not yet open for enrollment) | McGill University Health Center        | Phase II   | August 2022                        |
| <b>COMBINATIONS</b>   |  |  |            |                                    |
| <b>Perturbing of HIV reservoir with immune stimulation:</b> Fluarix, Pneumovax vaccines   | <a href="#">NCT02707692</a><br>(closed to enrollment)        | University of California, San Diego    | Not listed | January 2022                       |
| <b>MVA.HTI + ChAdOx1.HTI</b> therapeutic vaccines + <b>vesatolimod</b> (TLR7 agonist)   | <a href="#">NCT04364035</a><br>(closed to enrollment)        | Aelix Therapeutics                     | Phase IIa  | December 2022                      |
| <b>TITAN:</b> lefitolimod + 3BNC117 + 10-1074 (TLR9 agonist + broadly neutralizing antibodies)  | <a href="#">NCT03837756</a><br>(closed to enrollment)        | University of Aarhus                   | Phase IIa  | February 2023                      |
| <b>VRC07-523LS, CAP256V2LS, vesatolimod</b>   | <a href="#">NCT05281510</a><br>(not yet open for enrollment) | Gilead Sciences                        | Phase IIa  | January 2024                       |
| <b>Albuvirtide</b> (fusion inhibitor) + <b>3BNC117</b>  | <a href="#">NCT04819347</a><br>(not yet open for enrollment) | Frontier Biotechnologies Inc.          | Phase II   | December 2022                      |
| <b>ASC22</b> (anti-PD-L1 antibody) + <b>chidamide</b> (HDAC inhibitor)  | <a href="#">NCT05129189</a><br>(not yet open for enrollment) | Shanghai Public Health Clinical Center | Phase II   | May 2023                           |
| <b>MVA HIV-B +/- vedolizumab</b> (viral vector vaccine +/- anti- $\alpha_4\beta_7$ integrin antibody)   | <a href="#">NCT04120415</a><br>(not yet open for enrollment) | ANRS                                   | Phase II   | December 2022                      |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

## Research Toward a Cure April 14, 2022

Table 1. Current Clinical Trials (Cont.)

| Trial   | Trial Registry Identifier(s)  | Manufacturer/<br>Sponsor(s)           | Phase       | Estimated End<br>Date/Interim<br>Results   |
|---|---|---------------------------------------|-------------|--|
| <b>COMBINATIONS (Cont.)</b>   |   |                                       |             |  |
| <b>Research in Viral Eradication of HIV Reservoirs (RIVER):</b> ART, ChAdV63.HIVconsv & MVA.HIVconsv vaccines, vorinostat | <a href="#">NCT02336074</a><br><a href="#">UK CPMS18010</a><br>(closed to enrollment) | Imperial College London               | Phase II    | November 2022<br><a href="#">J Virus Erad. 2021 Sep 14;</a><br><a href="#">7(3):100056.</a><br><a href="#">Lancet. 2020 Mar 14;395(10227):888-898</a><br>AIDS 2018, Abstract TUAA0202LB ( <a href="#">slides</a> , <a href="#">video</a> ) |
| <b>UB-421 + chidamide</b> (antibody inhibitor of HIV binding to CD4 receptors + HDAC inhibitor)                           | <a href="#">NCT04985890</a><br>(not yet open for enrollment)                          | UBP Greater China (Shanghai) Co., Ltd | Phase II    | December 2025  |
| <b>UB-421 + chidamide</b>   | <a href="#">NCT05056974</a>   | United BioPharma                      | Phase II    | December 2023  |
| <b>vorinostat +/- tamoxifen</b> in postmenopausal women   | <a href="#">NCT03382834</a><br>(closed to enrollment)                                 | NIAID                                 | Phase II    | June 2023<br><a href="#">Clin Infect Dis. 2022 Feb 17:ciac136.</a><br>CROI 2020, <a href="#">Abstract 333</a> , <a href="#">Webcast</a><br>HIV Persistence Workshop 2019, Abstract OP 3.2 (see <a href="#">abstract book</a> )             |
| <b>Ad26.Mos4.HIV, MVA-BN-HIV, PGT121, PGDM1400, VRC07-523LS</b> (therapeutic vaccines, broadly neutralizing antibodies)   | <a href="#">NCT04983030</a><br>(not yet open for enrollment)                          | Boris Juelg, MD PhD                   | Phase I/IIa | March 2024   |
| <b>HIVARNA01.3, MVA vector HIV vaccine, 10-1074, romidepsin, HIVACAR01</b> (HIV RNA vaccine)                              | <a href="#">NCT03619278</a><br>(not yet open for enrollment)                          | David Garcia Cinca                    | Phase I/IIa | July 2021  |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure April 14, 2022

Table 1. Current Clinical Trials (Cont.)

| Trial  | Trial Registry Identifier(s)                                 | Manufacturer/ Sponsor(s)       | Phase      | Estimated End Date/Interim Results   |
|--|--|--------------------------------|------------|--|
| <b>COMBINATIONS (Cont.)</b>  |  |                                |            |  |
| <b>IMPAACT P1115 v2.0:</b> Very early intensive treatment of HIV-infected infants to achieve HIV remission (ART +/- VRC01)   | <a href="#">NCT02140255</a>                                  | IMPAACT                        | Phase I/II | December 2031<br>CROI 2022,<br><a href="#">Abstract 31</a>   |
| <b>panobinostat + pegylated interferon-alpha2a</b>   | <a href="#">NCT02471430</a>                                  | Massachusetts General Hospital | Phase I/II | December 2021<br>CROI 2022,<br><a href="#">Abstract 357</a><br>CROI 2020,<br><a href="#">Abstract 341</a>  |
| Therapeutic conserved element DNA vaccine ( <b>IL-12 adjuvanted p24CE</b> ), MVA vaccine boost ( <b>MVA/HIV62B</b> ), TLR9 agonist ( <b>lefitolimod</b> ) and broadly neutralizing antibodies ( <b>VRC07-523LS + 10-1074</b> ) | <a href="#">NCT04357821</a><br>(closed to enrollment)        | UCSF                           | Phase I/II | December 2024  |
| <b>elipovimab</b> (formerly GS-9722) +/- <b>vesatolimod</b>  | GS-US-420-3902 (no clinicaltrials.gov entry)                 | Gilead Sciences                | Phase Ib   | N/A  |
| <b>CD4-ZETA</b> gene-modified T cells +/- interleukin-2 (IL-2)   | <a href="#">NCT01013415</a><br>(closed to enrollment)        | University of Pennsylvania     | Phase I    | March 2022<br>CROI 2020,<br><a href="#">Abstract 337</a> ,<br><a href="#">Webcast</a><br><a href="#">Mol Ther. 2002</a><br><a href="#">Jun;5(6):788-97</a> |
| <b>HVRRICANE:</b> HIVIS DNA + MVA-CMDR vaccines +/- TLR4 agonist   | <a href="#">NCT04301154</a>                                  | PENTA Foundation               | Phase I    | September 2021   |
| <b>N-803</b> (recombinant human super agonist interleukin-15 complex) +/- <b>VRC07-523LS + 10-1074</b>   | <a href="#">NCT04340596</a>                                  | NIAID                          | Phase I    | November 2024  |
| <b>N-803, 3BNC117-LS, 10-1074-LS</b>   | <a href="#">NCT05245292</a><br>(not yet open for enrollment) | Rockefeller University         | Phase I    | September 2025   |
| <b>peginterferon alfa-2b + 3BNC117 + 10-1074</b> (BEAT-2)  | <a href="#">NCT03588715</a><br>(closed to enrollment)        | Wistar Institute               | Phase I    | October 2022<br>CROI 2022,<br><a href="#">Abstract 352</a>   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure April 14, 2022

Table 1. Current Clinical Trials (Cont.)

| Trial  | Trial Registry Identifier(s)                                 | Manufacturer/<br>Sponsor(s)                               | Phase       | Estimated End<br>Date/Interim<br>Results                            |
|--|--|---|-------------|---|
| <b>COMBINATIONS (Cont.)</b>  |  |   |             |   |
| <b>vorinostat + HXTC:</b> HIV 1 antigen expanded specific T cell therapy               | <a href="#">NCT03212989</a><br>(closed to enrollment)        | Julia Sung, MD, University of North Carolina, Chapel Hill | Phase I     | June 2022   |
| <b>CYTOKINES</b>   |  |   |             |   |
| <b>N-803</b> in acute HIV infection  | <a href="#">NCT04505501</a>                                  | Thai Red Cross AIDS Research Centre                       | Phase II    | August 2022   |
| Effect of <b>N-803</b> on B cell follicles   | <a href="#">NCT04808908</a>                                  | University of Minnesota                                   | Phase I     | February 2023   |
| <b>DUAL-AFFINITY RE-TARGETING (DART) MOLECULES</b>                                     |  |   |             |   |
| <b>MGD020 +/- MGD014</b>   | <a href="#">NCT05261191</a><br>(not yet open for enrollment) | MacroGenics   | Phase I     | July 2023   |
| <b>GENE THERAPIES</b>  |  |   |             |   |
| <b>EBT-101</b> (CRISPR/Cas9 targeting HIV provirus)                                    | <a href="#">NCT05144386</a>                                  | Excision BioTherapeutics                                  | Phase I/IIa | March 2025  |
| <b>LVgp120duoCAR-T cells</b>   | <a href="#">NCT04648046</a>                                  | Steven Deeks, UCSF  | Phase I/IIa | December 2024   |
| <b>Cal-1:</b> Dual anti-HIV gene transfer construct                                    | <a href="#">NCT02390297</a><br>(closed to enrollment)        | Calimmune   | Phase I/II  | October 2031<br>CROI 2020,<br><a href="#">Abstract 338</a>          |
| <b>SB-728-T</b> (autologous T cells gene-modified to disrupt CCR5 receptor expression) | <a href="#">NCT03666871</a><br>(closed to enrollment)        | Case Western Reserve University                           | Phase I/II  | February 2024   |
| <b>AGT103-T</b> (gene-modified HIV-specific CD4 T cells)                               | <a href="#">NCT04561258</a>                                  | American Gene Technologies International Inc.             | Phase I     | September 2022  |
| <b>CD4 CAR + SB-728mR</b> modified T cells   | <a href="#">NCT03617198</a><br>(closed to enrollment)        | University of Pennsylvania                                | Phase I     | December 2025<br><a href="#">CROI 2022</a><br>(James L. Riley)      |
| Chimeric Antigen Receptor (CAR)-T cell therapy   | <a href="#">NCT03240328</a>                                  | Guangzhou 8th People's Hospital                           | Phase I     | December 2022<br><a href="#">J Clin Invest. 2021 Aug 10;150211.</a> |
| <b>EBT-101</b> (long-term follow-up study)   | <a href="#">NCT05143307</a><br>(enrolling by invitation)     | Excision BioTherapeutics                                  | Phase I     | April 2037  |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure April 14, 2022

**Table 1. Current Clinical Trials (Cont.)**

| Trial   | Trial Registry Identifier(s)                                 | Manufacturer/<br>Sponsor(s)             | Phase      | Estimated End<br>Date/Interim<br>Results  |
|---|--|---|------------|---|
| <b>GENE THERAPIES (Cont.)</b>   |  |   |            |   |
| Long-term follow-up of HIV+ participants exposed to <b>SB-728-T</b> or <b>SB-728mR-T</b>        | <a href="#">NCT04201782</a><br>(enrolling by invitation)     | Sangamo Therapeutics                    | Phase I    | December 2033   |
| <b>SB-728mR-HSPC</b> (autologous hematopoietic stem/progenitor cells modified at the CCR5 gene) | <a href="#">NCT02500849</a><br>(closed to enrollment)        | City of Hope Medical Center             | Phase I    | December 2023   |
| <b>TCTIWHI</b> : Third-generation CAR-T-cell therapy  | <a href="#">NCT04863066</a><br>(not yet open for enrollment) | Beijing 302 Hospital                    | Phase I    | October 2022  |
| <b>GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS</b>                                      |  |   |            |   |
| Stem cells gene-modified with <b>Cal-1</b>  | <a href="#">NCT03593187</a>                                  | Assistance Publique - Hôpitaux de Paris | Phase I/II | January 2024<br><a href="#">Mol Ther Methods Clin Dev. 2019 Feb 26;13:303-309</a>   |
| Stem cells gene-modified with CCR5 shRNA/TRIM5alpha/TAR decoy                                   | <a href="#">NCT02797470</a>                                  | AIDS Malignancy Consortium              | Phase I/II | September 2024  |
| Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ)                | <a href="#">NCT02337985</a><br>(closed to enrollment)        | City of Hope Medical Center             | Phase I    | December 2022   |
| Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ) + busulfan     | <a href="#">NCT01961063</a><br>(closed to enrollment)        | City of Hope Medical Center             | Phase I    | December 2022   |
| <b>GONADOTROPIN-RELEASING HORMONE (GnRH) AGONISTS</b>   |  |   |            |   |
| triptorelin acetate depot   | <a href="#">NCT03536234</a>                                  | Immune System Regulation AB             | Phase II   | December 2021   |
| <b>IMAGING STUDIES</b>  |  |   |            |   |
| Imaging immune activation in HIV by PET-MR  | <a href="#">NCT03684655</a>                                  | University of California, San Francisco | Phase I    | October 2024  |
| Radiolabeled VRC01  | <a href="#">NCT03729752</a>                                  | University of California, San Francisco | Phase I    | October 2021<br><a href="#">Nat Commun. 2022 Mar 9;13(1):1219.</a><br>CROI 2020,<br><a href="#">Abstract 72,</a><br><a href="#">Webcast</a> |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure April 14, 2022

Table 1. Current Clinical Trials (Cont.)

| Trial   | Trial Registry Identifier(s)                                 | Manufacturer/ Sponsor(s)  | Phase      | Estimated End Date/Interim Results  |
|---|--|---|------------|---|
| <b>IMMUNE CHECKPOINT INHIBITORS</b>   |  |   |            |   |
| <b>durvalumab</b> (anti-PD-L1 antibody) in solid tumors   | <a href="#">NCT03094286</a><br>(closed to enrollment)        | Spanish Lung Cancer Group                                       | Phase II   | April 2022<br><a href="#">JAMA Oncol. 2020 Jul 1;6(7):1063-1067</a>   |
| <b>budigalimab</b> (anti-PD-1 antibody)   | <a href="#">NCT04223804</a>                                  | AbbVie  | Phase Ib   | February 2023   |
| <b>budigalimab</b> (anti-PD-1 antibody)   | <a href="#">NCT04799353</a>                                  | AbbVie  | Phase I    | October 2022  |
| <b>NIVO-LD</b> : Low dose <b>nivolumab</b> in adults living with HIV on antiretroviral therapy  | <a href="#">NCT05187429</a><br>(not yet open for enrollment) | University of Melbourne   | Phase I/II | January 2024  |
| <b>nivolumab</b> (anti-PD-1 antibody) + <b>ipilimumab</b> (anti-CTLA-4 antibody) in treating patients with advanced HIV associated solid tumors | <a href="#">NCT02408861</a>                                  | National Cancer Institute (NCI)                                 | Phase I    | July 2022<br><a href="#">Clin Infect Dis. 2021 ciaa1530</a><br>HIV Persistence Workshop 2019,<br><a href="#">Abstract OP 5.5 Journal of Clinical Oncology 36, no. 15 suppl</a>  |
| <b>pembrolizumab</b> (anti-PD-1 antibody) in treating patients with HIV and relapsed, refractory, or disseminated malignant neoplasms           | <a href="#">NCT02595866</a>                                  | National Cancer Institute (NCI)                                 | Phase I    | November 2024<br><a href="#">Sci Transl Med. 2022; 14(629):eabl3836</a><br><a href="#">JAMA Oncol. 2019 Jun 2</a><br>CROI 2019,<br><a href="#">Abstract 27, Webcast</a><br>CROI 2018,<br><a href="#">Abstract 656LB</a> |
| <b>pembrolizumab</b> (anti-PD-1 antibody) single dose   | <a href="#">NCT03239899</a>                                  | National Institute of Neurological Disorders and Stroke (NINDS) | Phase I    | December 2024   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)



# Research Toward a Cure April 14, 2022

Table 1. Current Clinical Trials (Cont.)

| Trial   | Trial Registry Identifier(s)   | Manufacturer/<br>Sponsor(s)  | Phase        | Estimated End<br>Date/Interim<br>Results  |
|---|--|--|--------------|---|
| <b>LATENCY-REVERSING AGENTS (Cont.)</b>   |  |  |              |   |
| arsenic trioxide  | <a href="#">NCT03980665</a>  | Guangzhou 8th People's Hospital  | Phase I      | December 2022   |
| decitabine, romidepsin  | <a href="#">NCT05230368</a><br>(not yet open for enrollment)   | ANRS   | Phase I      | April 2026  |
| Euphorbia kansui  | <a href="#">NCT04503928</a><br>(not yet open for enrollment)   | Shanghai Public Health Clinical Center   | Phase I      | December 2022   |
| Kansui (traditional Chinese medicine containing ingenols)   | <a href="#">NCT02531295</a><br>(Suspended - temporary pause on non-COVID clinical trial recruitment at study site) | UCSF   | Phase I      | June 2023   |
| <b>mTOR INHIBITORS</b>  |  |  |              |   |
| metformin   | <a href="#">NCT04500678</a>  | University of Hawaii   | Phase II/III | December 2022<br><a href="#">AIDS Res Hum Retroviruses. 2020 Nov 5.</a>                               |
| <b>STEM CELL TRANSPLANTATION</b>  |  |  |              |   |
| <b>IMPAACT P1107:</b> Cord blood transplantation using CCR5-Δ32 donor cells for the treatment of HIV and underlying disease | <a href="#">NCT02140944</a><br>(closed to enrollment)  | International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) | N/A          | April 2022<br>CROI 2022,<br><a href="#">Abstract 65</a><br>ASH 2018,<br><a href="#">Abstract 2184</a> |
| Cord blood transplant with OTS for the treatment of HIV+ hematologic cancers  | <a href="#">NCT04083170</a>  | Fred Hutchinson Cancer Research Center   | Phase II     | December 2025   |
| <b>STIMULANTS</b>   |  |  |              |   |
| <b>EMRLHD:</b> Effect of methamphetamine on residual latent HIV disease study   | <a href="#">NCT03825536</a>  | University of California, San Francisco  | Phase IV     | June 2023   |
| <b>THERAPEUTIC VACCINES</b>   |  |  |              |   |
| <b>BELIEVE:</b> BCG vaccination effect on latent reservoir size in treated HIV-1 infection                                  | <a href="#">NCT05004038</a>  | University of Zurich   | Phase IIa    | January 2024  |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure April 14, 2022

**Table 1. Current Clinical Trials (Cont.)**

| Trial   | Trial Registry Identifier(s)                                 | Manufacturer/<br>Sponsor(s)                                | Phase     | Estimated End<br>Date/Interim<br>Results                      |
|---|--|--|-----------|---|
| <b>THERAPEUTIC VACCINES (Cont.)</b>   |  |  |           |   |
| <b>ChAdOx1.HTI, MVA.HTI, ConM SOSIP.v7 gp140</b>  | <a href="#">NCT05208125</a><br>(not yet open for enrollment) | IrsiCaixa  | Phase I   | May 2023  |
| <b>DC-HIV04:</b> a1DC + inactivated whole autologous HIV, a1DC + conserved HIV peptides         | <a href="#">NCT03758625</a>                                  | Sharon Riddler, University of Pittsburgh                   | Phase I   | May 2023  |
| <b>DNA.HTI + MVA.HTI + ChAdOx1.HTI</b> (DNA + viral vector vaccines) (ATI extension)            | <a href="#">NCT04385875</a><br>(closed to enrollment)        | Fundacio Lluita Contra la SIDA                             | Phase I   | February 2022   |
| <b>MVA.tHIVconsv3 +/- MVA.tHIVconsv4</b> (viral vectors)  | <a href="#">NCT03844386</a><br>(closed to enrollment)        | University of North Carolina, Chapel Hill                  | Phase I   | June 2022   |
| <b>NETI:</b> Trimer 4571 therapeutic vaccination  | <a href="#">NCT04985760</a>                                  | Madhuchhanda Choudhary                                     | Phase I   | January 2025  |
| <b>TREATMENT INTENSIFICATION/EARLY TREATMENT</b>  |  |  |           |   |
| Antiretroviral regime for viral eradication in newborns   | <a href="#">NCT02712801</a><br>(closed to enrollment)        | National Center for Women and Children's Health, China CDC | Phase IV  | December 2022   |
| <b>DGVTAf:</b> Immediate initiation of antiretroviral therapy during "hyperacute" HIV infection | <a href="#">NCT02656511</a><br>(closed to enrollment)        | UCSF   | Phase IV  | April 2023  |
| <b>AAHIV:</b> Antiretroviral therapy for acute HIV infection                                    | <a href="#">NCT00796263</a>                                  | South East Asia Research Collaboration with Hawaii         | Phase III | June 2033<br><a href="#">See supplemental references page</a> |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure April 14, 2022

**Table 1. Current Clinical Trials (Cont.)**

| Trial   | Trial Registry Identifier(s)                          | Manufacturer/<br>Sponsor(s)     | Phase        | Estimated End Date/Interim Results   |
|---|---|---------------------------------|--------------|--|
| <b>TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)</b>                    |   |                                 |              |  |
| <b>EIT:</b> Early infant HIV treatment in Botswana                          | <a href="#">NCT02369406</a><br>(closed to enrollment) | Harvard School of Public Health | Phase II/III | May 2022<br>CROI 2022,<br><a href="#">Abstract 712</a><br><a href="#">Clin Infect Dis.</a><br><a href="#">2021 ciab143</a><br><a href="#">Clin Infect Dis.</a><br><a href="#">2020 Jan 12.</a><br><a href="#">Sci Transl Med.</a><br><a href="#">2019 Nov</a><br><a href="#">27:11(520). pii: eaax7350</a><br>CROI 2019,<br><a href="#">Poster abstract 826</a><br>CROI 2018,<br><a href="#">Abstract 136</a> ,<br><a href="#">Webcast</a> |
| <b>EARLIER:</b> Early ART to limit infection and establishment of reservoir | <a href="#">NCT02859558</a><br>(closed to enrollment) | AIDS Clinical Trials Group      | Phase II     | September 2023<br><a href="#">Clin Infect Dis.</a><br><a href="#">2021 Aug</a><br><a href="#">2:73(3):e643-e651</a>  |

**Table 2. Current Observational Studies**

| Trial   | Trial Registry Identifier(s)                                  | Manufacturer/ Sponsor(s)                      | Phase | Estimated End Date/Interim Results   |
|---|---|---|-------|--|
| <b>2000HIV:</b> 2000 HIV human functional genomics partnership program  | <a href="#">NCT03994835</a><br>(closed to enrollment)         | Radboud University                            | N/A   | December 2023  |
| <b>2000HIVTrained:</b> 2000 HIV trained innate immunity in HIV elite controllers  | <a href="#">NCT04968717</a><br>(closed to enrollment)         | Radboud University                            | N/A   | December 2022  |
| Accurate staging of immuno-virological dynamics during acute HIV infection (ACS)  | <a href="#">NCT03449706</a>                                   | University Hospital, Ghent                    | N/A   | January 2023   |
| Analytic treatment interruption (ATI) to assess HIV cure  | <a href="#">NCT02437526</a><br>(enrolling by invitation only) | Mayo Clinic                                   | N/A   | May 2025<br><a href="#">PLoS Med. 2017 Nov 28;14(11):e1002461.</a>   |
| <b>ANRS CO24 OncoVIHAC:</b> Immune checkpoint inhibitors in HIV+ individuals with cancers   | <a href="#">NCT03354936</a>                                   | Inserm-ANRS                                   | N/A   | June 2022<br><a href="#">Cells. 2022 Mar 17;11(6):1015.</a><br><a href="#">AIDS 2020, Abstract OAB0203</a> |
| <b>ATGALIG-HIV:</b> Study of autophagy and the effects of GALIG gene products in HIV-1+ patients on antiretroviral therapy since primary infection, chronic phase, or never treated   | <a href="#">NCT04160455</a>                                   | Centre Hospitalier Régional d'Orléans         | N/A   | November 2029  |
| <b>BICTEVOIR:</b> A study to determine the cartography of virologic reservoir related to antiretroviral concentrations in HIV-1+ patients on first line treatment containing bictegravir, emtricitabine and tenofovir alafenamide | <a href="#">NCT05222945</a><br>(not yet open for enrollment)  | ANRS  | N/A   | March 2024   |
| <b>CHRONO:</b> A prospective cohort for ex vivo cure studies with chronic HIV+ patients in the Netherlands  | <a href="#">NCT04888754</a>                                   | Erasmus Medical Center                        | N/A   | January 2034   |
| <b>CODEX</b> (the "Extreme" cohort, ANRS CO21)  | <a href="#">NCT01520844</a>                                   | Inserm-ANRS                                   | N/A   | September 2023<br><a href="#">See supplemental references page</a>   |
| Developing a functional cure for HIV disease: Clinical specimen collection from HIV+ individuals  | <a href="#">NCT03215004</a>                                   | American Gene Technologies International Inc. | N/A   | February 2021  |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

## Research Toward a Cure April 14, 2022

**Table 2. Current Observational Studies (Cont.)**

| Trial  | Trial Registry Identifier(s)  | Manufacturer/<br>Sponsor(s)   | Phase | Estimated End<br>Date/Interim Results  |
|--|---|---|-------|--|
| <b>DOLUVOIR:</b> Cartography of virologic reservoir related to antiretroviral concentrations in HIV-1+ patients on first line treatment containing dolutegravir and associated nucleoside/nucleotide reverse transcriptase inhibitors backbone | <a href="#">NCT04133012</a>   | Inserm-ANRS   | N/A   | November 2023  |
| Establish and characterize an acute HIV infection cohort in a high-risk population   | <a href="#">NCT00796146</a>   | Southeast Asia Research Collaboration with Hawaii                     | N/A   | July 2033<br><a href="#">See supplemental references page</a>  |
| Evaluation of the role of HIV-1 Tat protein and anti-Tat immune response in HIV reservoir (ISS OBS T-005)  | <a href="#">NCT04263207</a>   | Barbara Ensoli, MD, PhD, Istituto Superiore di Sanità                 | N/A   | December 2023  |
| Expectation, motivation and experience of HIV+ patients regarding participation to an HIV cure-related clinical trial (AMEP-EHVA T02)  | <a href="#">NCT05280392</a><br>(not yet open for enrollment)          | ANRS  | N/A   | March 2025   |
| <b>EX VIVO:</b> Ex vivo characterization and targeting of the latent HIV infected reservoir to cure HIV  | <a href="#">NCT05215704</a>   | Erasmus Medical Center  | N/A   | December 2030  |
| <b>FRESH</b> (Females rising through education, support, and health)   | <a href="#">Ragon Institute webpage</a> (no clinicaltrials.gov entry) | Ragon Institute of MGH, MIT and Harvard                               | N/A   | N/A<br><a href="#">See supplemental references page</a>  |
| <b>FXR#2:</b> Selection of farnesoid X receptor (FXR) ligands on the reactivation of latent HIV proviruses   | <a href="#">NCT05219916</a><br>(not yet open for enrollment)          | Hospices Civils de Lyon   | N/A   | September 2024   |
| <b>HEATHER:</b> HIV reservoir targeting with early antiretroviral therapy  | UK CPMS17589  | University of Oxford/Medical Research Council/British HIV Association | N/A   | September 2019<br><a href="#">Front Immunol. 2021; 12: 647688.</a><br><a href="#">J Infect Dis. 2019 Nov 28. pii: jiz563</a><br><a href="#">Mucosal Immunol. 2019 Sep;12(5):1212-1219.</a> |
| <b>HIV-Mercuri:</b> HIV study on measuring the reservoir on cellular level to cure infection   | <a href="#">NCT04305665</a>   | University Hospital, Ghent  | N/A   | December 2025  |
| Host & viral factors associated with HIV elite control   | UK CPMS16146  | University College London Hospitals NHS Foundation Trust              | N/A   | May 2021   |
| HUSH restriction in HIV+ patients  | <a href="#">NCT04172480</a>   | Inserm-ANRS   | N/A   | September 2023   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

## Research Toward a Cure April 14, 2022

**Table 2. Current Observational Studies (Cont.)**

| Trial  | Trial Registry Identifier(s)   | Manufacturer/ Sponsor(s)         | Phase | Estimated End Date/Interim Results  |
|--|--|----------------------------------|-------|---|
| <b>iCHIP</b> : Effect of immune checkpoint inhibitors on HIV persistence   | <a href="http://hivcure.com.au">hivcure.com.au</a> (no registry entry) | University of Melbourne          | N/A   | N/A<br><a href="#">J Immunol Methods. 2021 Dec 1;113198</a><br><a href="#">AIDS. 2021 Apr 15.</a><br>CROI 2020, <a href="#">Abstract 334</a>  |
| <b>IciStem</b> : Collaborative project to guide and investigate the potential for HIV cure in HIV+ patients requiring allogeneic stem cell transplantation for hematological disorders | <a href="#">IciStem website</a> (no clinicaltrials.gov entry)          | amfAR                            | N/A   | N/A<br>CROI 2020, <a href="#">Abstract 339</a> , <a href="#">Abstract 348LB</a><br><a href="#">Lancet HIV 2020 Mar 9.</a><br>HIV Persistence Workshop 2019, <a href="#">Abstract OP 4.5</a><br><a href="#">Nature. 2019 Apr;568(7751):244-248.</a><br>CROI 2019, <a href="#">Poster abstract 394</a><br><a href="#">Ann Intern Med. 2018;169(10):674-683.</a> |
| Identification and quantification of HIV CNS latency biomarkers  | <a href="#">NCT02989285</a>  | St Vincent's Hospital, Sydney    | N/A   | December 2020   |
| Impact of ART adherence on HIV persistence and inflammation  | <a href="#">NCT02797093</a><br>(closed to enrollment)                  | University of Colorado, Denver   | N/A   | October 2021  |
| Investigation of the impact of inducible, replication-competent latent HIV-1 as an impediment to HIV/AIDS cure in the context of sustained viral suppression                           | <a href="#">NCT04938518</a>  | Kenya Medical Research Institute | N/A   | April 2022  |
| <b>LAMIVIH</b> : Evolution of HIV reservoir, inflammation, and microbiota footprint of PLWH switching to long-acting injectable treatment  | <a href="#">NCT05303337</a><br>(not yet open for enrollment)           | Hôpital Européen Marseille       | N/A   | March 2024  |
| Long-term clinical, immunologic, and virologic profiles of children who received early treatment for HIV   | <a href="#">NCT05154513</a>  | IMPAACT                          | N/A   | November 2027   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 2. Current Observational Studies (Cont.)**

| Trial   | Trial Registry Identifier(s)                             | Manufacturer/<br>Sponsor(s)   | Phase | Estimated End<br>Date/Interim Results  |
|---|--|---|-------|--|
| Long-term effects of ART in acute HIV infection   | <a href="#">ChiCTR1800015006</a>                         | Key Laboratory of AIDS Immunology of National Health and Family Planning Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University | N/A   | June 2021  |
| Measurement for viral reservoir and immune function in HIV-1+ patients under antiretroviral therapy   | <a href="#">NCT04068441</a>                              | National Taiwan University Hospital   | N/A   | December 2021<br><a href="#">J Acquir Immune Defic Syndr. 2021 Apr 1;86(4):500-508</a> |
| Post analytic treatment interruption study  | <a href="#">NCT02761200</a>                              | South East Asia Research Collaboration with Hawaii  | N/A   | March 2031   |
| <b>PRIMO</b> (ANRS CO6): Primary infection cohort   | <a href="#">NCT03148964</a>                              | Inserm-ANRS   | N/A   | December 2022<br><a href="#">See supplemental references page</a>                      |
| <b>RESERVIH32</b> : Bioclinical evaluation of two biomarkers of aviremic HIV-1 in CD4 T cells of adults undergoing treatment                                      | <a href="#">NCT03940521</a>                              | Centre Hospitalier Universitaire de Nîmes   | N/A   | September 2022   |
| Role of the IL-33/amphiregulin pathway as a potential therapeutic target in HIV infection   | <a href="#">NCT03622177</a>                              | Inserm-ANRS   | N/A   | September 2023   |
| <b>Saturne-HIV</b> : Sequential analysis before and after treatment initiation to unravel the role of naturally occurring extracellular vesicles in HIV infection | <a href="#">NCT04653610</a>                              | University Hospital, Ghent  | N/A   | January 2025   |
| <b>SCOPE-ATI</b> : SCOPE analytic treatment interruption protocol   | <a href="#">NCT04359186</a><br>(enrolling by invitation) | UCSF  | N/A   | June 2024  |
| <b>TESOVIR</b> : Tracking and exploring the source of viral rebound (ART interruption)  | <a href="#">NCT03117985</a>                              | Centre Hospitalier Régional d'Orléans   | N/A   | September 2022   |
| The Gemini Study: Safety and survival of genetically modified white blood cells in HIV+ twins   | <a href="#">NCT04799483</a><br>(closed to enrollment)    | NIAID   | N/A   | January 2030   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

## Research Toward a Cure April 14, 2022

**Table 2. Current Observational Studies (Cont.)**

| Trial  | Trial Registry Identifier(s)                       | Manufacturer/<br>Sponsor(s)                                     | Phase | Estimated End<br>Date/Interim Results   |
|--|--|---|-------|---|
| The Last Gift Study (for people with HIV and less than 6 months life expectancy due to terminal illness) | <a href="#">UCSD study website</a>                 | University of California, San Diego (UCSD)                      | N/A   | N/A<br><a href="#">PLoS One. 2021 May 7;16(5):e0250882.</a><br><a href="#">J Clin Invest. 2020 Jan 7</a><br>HIV Persistence Workshop 2019, Abstract PP 5.7.5 (see <a href="#">abstract book</a> ) |
| The use of leukapheresis to support HIV pathogenesis studies   | <a href="#">NCT01161199</a>                        | University of California, San Francisco                         | N/A   | December 2022   |
| Thinking and memory problems in people with HIV  | <a href="#">NCT01875588</a>                        | National Institute of Neurological Disorders and Stroke (NINDS) | N/A   | February 2037   |
| <b>TRESAX:</b> T follicular helper reservoir in axillary lymph nodes study                               | <a href="#">hivcure.com.au</a> (no registry entry) | Kirby Institute   | N/A   | N/A   |



**Table 3. Completed Studies**

| Trial   | Trial Registry Identifier(s)        | Manufacturer/ Sponsor(s)  | Phase      | Published/Presented Data  |
|---|-------------------------------------|---|------------|---|
| <b>ADOPTIVE IMMUNOTHERAPY</b>   |                                     |   |            |   |
| Early ART in combination with autologous HIV-specific cytotoxic T lymphocyte (CTL) infusion | <a href="#">NCT02231281</a>         | Yongtao Sun, MD, PhD, Tangdu Hospital, the Fourth Military Medical University | Phase III  | N/A   |
| Reconstitution of HIV-specific immunity against HIV   | <a href="#">NCT02563509</a>         | Guangzhou 8th People's Hospital   | Phase I/II | N/A   |
| HIV-specific memory CD8 T cells adoptive immunotherapy                                      | <a href="#">ChiCTR-ICR-15005775</a> | Beijing You'an Hospital, Capital Medical University                           | Phase I    | <a href="#">Front Immunol. 2019 Mar 18;10:437</a>   |
| <b>HXTC</b> : HIV 1 antigen expanded specific T cell therapy                                | <a href="#">NCT02208167</a>         | University of North Carolina, Chapel Hill                                     | Phase I    | <a href="#">Mol Ther. 2018 Oct 3;26(10):2496-2506.</a>  |
| <b>ANTIBODIES</b>   |                                     |   |            |   |
| <b>3BNC117</b> (broadly neutralizing monoclonal antibody)                                   | <a href="#">NCT02446847</a>         | Rockefeller University  | Phase II   | <a href="#">Nature. 2016 Jul 28; 535(7613):556–560</a>  |
| <b>3BNC117</b>  | <a href="#">NCT02588586</a>         | Rockefeller University  | Phase II   | N/A   |
| <b>UB-421</b> (antibody inhibitor of HIV binding to CD4 receptors)                          | <a href="#">NCT02369146</a>         | United BioPharma  | Phase II   | <a href="#">N Engl J Med. 2019 Apr 18;380(16):1535-1545</a>   |
| <b>vedolizumab</b> (anti- $\alpha_4\beta_7$ integrin antibody)                              | <a href="#">NCT03577782</a>         | Hospitales Universitarios Virgen del Rocío                                    | Phase II   | XI Congreso Nacional GeSIDA, Abstract PO-48 ( <a href="#">slides</a> , <a href="#">video</a> )  |
| <b>VRC01</b> (broadly neutralizing monoclonal antibody)                                     | <a href="#">NCT02664415</a>         | National Institute of Allergy and Infectious Diseases (NIAID)                 | Phase II   | <a href="#">J Clin Invest. 2020 Jun 1;130(6):3299-3304.</a><br><a href="#">Lancet HIV. 2019 May;6(5):e297-e306.</a><br>IAS 2017, Abstract <a href="#">TUAB0106LB</a> ( <a href="#">slides</a> , <a href="#">video</a> ) |
| <b>VRC01</b> (broadly neutralizing antibody) in infants                                     | <a href="#">NCT03208231</a>         | NIAID   | Phase I/II | N/A   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure April 14, 2022

**Table 3. Completed Studies (Cont.)**

| Trial  | Trial Registry Identifier(s)                        | Manufacturer/ Sponsor(s)   | Phase      | Published/Presented Data  |
|--|---|--|------------|---|
| <b>ANTIBODIES (Cont.)</b>  |   |  |            |   |
| <b>VRC01LS + 10-1074</b> (broadly neutralizing antibodies) in early-treated children | <a href="#">NCT03707977</a>                         | NIAID  | Phase I/II | CROI 2022, <a href="#">Abstract 32</a><br>CROI 2021, <a href="#">Abstract 609</a> , <a href="#">Webcast</a> |
| <b>10-1074</b> (broadly neutralizing monoclonal antibody)                            | <a href="#">NCT02511990</a>                         | Rockefeller University   | Phase I    | <a href="#">Nat Med. 2017 Feb;23(2):185-191</a>   |
| <b>10-1074-LS + 3BNC117-LS</b> (long-acting broadly neutralizing antibodies)         | <a href="#">NCT03554408</a>                         | Rockefeller University   | Phase I    | N/A   |
| <b>3BNC117</b>   | <a href="#">NCT02018510</a>                         | Rockefeller University   | Phase I    | <a href="#">Nature. 2015 Jun 25;522(7557):487-91</a>  |
| <b>3BNC117 + 10-1074</b>   | <a href="#">NCT03571204</a>                         | NIAID  | Phase I    | N/A   |
| <b>3BNC117 + 10-1074</b>   | <a href="#">NCT02825797</a>                         | Rockefeller University   | Phase I    | <a href="#">Nature. 2018 Sep;561(7724):479-484.</a><br><a href="#">Nat Med. 2018 Sep 26.</a>                |
| <b>3BNC117 + 10-1074</b>   | <a href="#">NCT03526848</a>                         | Rockefeller University   | Phase I    | CROI 2022, <a href="#">Abstract 361</a>   |
| <b>3BNC117-LS + 10-1074-LS</b> in viremic HIV+ individuals                           | <a href="#">NCT04250636</a>                         | Rockefeller University   | Phase I    | CROI 2022, <a href="#">Abstract 140</a>   |
| <b>3BNC117-LS</b>  | <a href="#">NCT03254277</a>                         | Rockefeller University   | Phase I    | N/A   |
| <b>CHERUB 001</b><br>Intravenous immunoglobulin in primary HIV infection             | No clinicaltrials.gov entry                         | CHERUB (Collaborative HIV Eradication of viral Reservoirs: UK BRC) | N/A        | <a href="#">HIV Med. 2017 Jul 18. doi: 10.1111/hiv.12524.</a>   |
| <b>elipovimab</b> (formerly GS-9722; PGT121-derived broadly neutralizing antibody)   | GS-US-420-3902<br><a href="#">Adisinsight entry</a> | Gilead Sciences  | Phase I    | CROI 2020, <a href="#">Abstract 39</a> , <a href="#">Webcast</a>  |
| <b>PGDM1400 +/- PGT121 +/- VRC07-523LS</b> (broadly neutralizing antibodies)         | <a href="#">NCT03205917</a>                         | International AIDS Vaccine Initiative                              | Phase I    | CROI 2022, <a href="#">Abstract 139</a>   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure April 14, 2022

Table 3. Completed Studies (Cont.)

| Trial  | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)              | Phase    | Published/Presented Data   |
|--|------------------------------|---------------------------------------|----------|--|
| <b>ANTIBODIES (Cont.)</b>  |                              |                                       |          |  |
| PGT121   | <a href="#">NCT02960581</a>  | International AIDS Vaccine Initiative | Phase I  | <a href="#">Nat Med. 2021 Oct 7. CROI 2019, Abstract 145, Webcast</a>  |
| vedolizumab  | <a href="#">NCT02788175</a>  | NIAID                                 | Phase I  | AIDS 2018, <a href="#">WESS0102</a>  |
| VRC01 + 10-1074  | <a href="#">NCT03831945</a>  | NIAID                                 | Phase I  | N/A  |
| VRC01 in acute HIV infection                                       | <a href="#">NCT02591420</a>  | NIAID                                 | Phase I  | N/A  |
| VRC01  | <a href="#">NCT02411539</a>  | NIAID                                 | Phase I  | N/A  |
| VRC01  | <a href="#">NCT02471326</a>  | NIAID                                 | Phase I  | <a href="#">N Engl J Med. 2016 Nov 24;375(21):2037-2050</a>  |
| VRC01  | <a href="#">NCT02463227</a>  | NIAID                                 | Phase I  | <a href="#">N Engl J Med. 2016 Nov 24;375(21):2037-2050</a><br>CROI 2016, Abstract 32LB, <a href="#">Webcast</a> |
| VRC01  | <a href="#">NCT01950325</a>  | NIAID                                 | Phase I  | <a href="#">Sci Transl Med. 2015 Dec 23;7(319):319ra206</a>  |
| VRC01LS, VRC07-523LS (long-acting broadly neutralizing antibodies) | <a href="#">NCT02840474</a>  | NIAID                                 | Phase I  | IAS 2019, <a href="#">Abstract WEAA0305LB (video, at 45:36)</a>  |
| <b>ANTI-FIBROTIC</b>   |                              |                                       |          |  |
| ACE inhibitors   | <a href="#">NCT01535235</a>  | UCSF/amfAR                            | Phase IV | <a href="#">Pathogens and Immunity. 2017;2(3):310-34.</a>  |
| losartan   | <a href="#">NCT01852942</a>  | University of Minnesota               | Phase II | CROI 2020, <a href="#">Abstract 277</a>  |
| telmisartan  | <a href="#">NCT01928927</a>  | AIDS Clinical Trials Group            | Phase II | CROI 2019, <a href="#">Abstract 395</a><br><a href="#">J Infect Dis. 2018 217(11):1770-1781</a>                  |
| telmisartan  | <a href="#">NCT02170246</a>  | Yale University                       | Phase I  | CROI 2019, <a href="#">Abstract 300</a>  |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

## Research Toward a Cure April 14, 2022

Table 3. Completed Studies (Cont.)

| Trial  | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                               | Phase      | Published/Presented Data   |
|--|------------------------------|--|------------|--|
| <b>ANTI-INFLAMMATORY</b>   |                              |  |            |  |
| <b>CD24Fc</b> (human CD24 extracellular domain and human IgG1 Fc fusion protein)           | <a href="#">NCT03960541</a>  | Oncolmmune, Inc.                                       | Phase II   | “Terminated (Business Reasons)”  |
| High dose <b>vitamin D</b> supplementation   | <a href="#">NCT03426592</a>  | University of Melbourne                                | Phase II   | CROI 2022, <a href="#">Abstract 355</a>  |
| <b>CC-11050</b> (phosphodiesterase-4 inhibitor)  | <a href="#">NCT02652546</a>  | NIAID  | Phase I    | AIDS 2018, <a href="#">Poster abstract LBPEB021</a>  |
| <b>ANTI-PROLIFERATIVE</b>  |                              |  |            |  |
| <b>mycophenolate mofetil (MMF)</b>   | <a href="#">NCT03262441</a>  | Fred Hutchinson Cancer Research Ctr                    | Phase I    | CROI 2020, <a href="#">Abstract 340</a>  |
| <b>ANTIRETROVIRAL THERAPY</b>  |                              |  |            |  |
| <b>dolutegravir</b> in reservoirs  | <a href="#">NCT02924389</a>  | Emory University                                       | Phase IV   | <a href="#">AIDS. 2018 Sep 24;32(15):2151-2159.</a>  |
| HIV reservoir dynamics after switching to dolutegravir in patients on a PI/r based regimen | <a href="#">NCT02513147</a>  | Hospital Universitari Vall d'Hebron Research Institute | Phase IV   | N/A  |
| <b>raltegravir or efavirenz + tenofovir + emtricitibine</b>                                | <a href="#">NCT00734344</a>  | University of Alabama at Birmingham                    | Phase IV   | N/A  |
| doravirine concentrations and antiviral activity in cerebrospinal fluid                    | <a href="#">NCT04079452</a>  | Fundacio Lluita Contra la SIDA                         | Phase III  | <a href="#">Clin Infect Dis. 2021 Sep 21;ciab835.</a>  |
| <b>ABX464</b>  | <a href="#">NCT02735863</a>  | Abivax S.A.  | Phase II   | <a href="#">J. Virus Eradication 2019;5:10–22</a>  |
| <b>ABX464</b>  | <a href="#">NCT02990325</a>  | Abivax S.A.  | Phase I/II | <a href="#">Clin Infect Dis. 2021 Aug 26;ciab733.</a><br>CROI 2020, <a href="#">Abstract 335</a><br>HIV Persistence Workshop 2019, Abstract OP 8.3 (see <a href="#">abstract book</a> )<br>16th European Meeting on HIV & Hepatitis 2018, <a href="#">presentation</a> |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

| Trial  | Trial Registry Identifier(s)        | Manufacturer/ Sponsor(s)                | Phase    | Published/Presented Data  |
|--|-------------------------------------|---|----------|---|
| <b>ANTIRETROVIRAL THERAPY IN HIV CONTROLLERS</b> |                                     |   |          |   |
| emtricitabine + rilpivirine + tenofovir          | <a href="#">NCT01777997</a>         | AIDS Clinical Trials Group/NIAID        | Phase IV | <a href="#">J Infect Dis. 2020 June 4;:jiaa294</a><br><a href="#">Clin Infect Dis. 2019 May 25.</a><br>CROI 2019, <a href="#">Poster abstract 508</a><br>CROI 2018, <a href="#">Poster abstract 229</a> |
| raltegravir + tenofovir + emtricitabine          | <a href="#">NCT01025427</a>         | University of California, San Francisco | Phase IV | <a href="#">PLoS Pathog. 2013;9(10):e1003691</a>  |
| <b>ASSEMBLY INHIBITORS</b>                       |                                     |   |          |   |
| BIT225   | <a href="#">ACTRN12617000025336</a> | Biotron Limited                         | Phase II | <a href="#">J Infect Dis. 2021 Jun 4;223(11):1914-1922.</a><br>CROI 2020, <a href="#">Abstract 506</a><br><a href="#">HIV DART 2018</a>   |
| BIT225   | <a href="#">ACTRN12612000696897</a> | Biotron Limited                         | Phase I  | <a href="#">J Antimicrob Chemother. 2016 Mar;71(3):731-8</a>  |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

Table 3. Completed Studies (Cont.)

| Trial  | Trial Registry Identifier(s)                          | Manufacturer/ Sponsor(s)   | Phase      | Published/Presented Data   |
|--|---|--|------------|--|
| <b>COMBINATIONS</b>  |   |  |            |  |
| maraviroc, dolutegravir, dendritic cell vaccine, auranofin, nicotinamide | <a href="#">NCT02961829</a>                           | Federal University of São Paulo  | Not listed | <a href="#">CROI 2021, Abstract 313</a><br><a href="#">AIDS Res Ther. 2022 Jan 12;19(1):2.</a><br>AIDS 2020, <a href="#">Abstract OAXLB0105</a><br>HIV Persistence Workshop 2019, Abstract OP 8.6 (see <a href="#">abstract book</a> )<br><a href="#">Int J Antimicrob Agents. 2019 Aug 5. pii: S0924-8579(19)30212-2.</a><br>CROI 2019, <a href="#">Poster abstract 399</a><br>AIDS 2018, Abstract WEPDB0105 ( <a href="#">slides</a> , <a href="#">video</a> ) |
| ROADMAP: romidepsin + 3BNC117  | <a href="#">NCT02850016</a>                           | Rockefeller University   | Phase IIa  | <a href="#">Lancet Microbe. 2022 Mar;3(3):e203-e214</a><br>CROI 2020, <a href="#">Abstract 38</a> , <a href="#">Webcast</a>  |
| Adoptive transfer of haploidentical natural killer cells and IL-2        | <a href="#">NCT03346499</a>                           | University of Minnesota - Clinical and Translational Science Institute | Phase II   | N/A  |
| eCLEAR: romidepsin + 3BNC117   | <a href="#">NCT03041012</a><br>(closed to enrollment) | Aarhus University Hospital   | Phase II   | CROI 2022, <a href="#">Abstract 62</a> , <a href="#">Abstract 122</a>  |
| ERAMUNE-01<br>(antiretroviral intensification +/- interleukin-7)         | <a href="#">NCT01019551</a>                           | ORVACS/Cytheris SA/Merck Sharp & Dohme Corp./Pfizer                    | Phase II   | <a href="#">AIDS. 2016 Jan;30(2):221-30</a>  |
| ERAMUNE-02<br>(DNA/Ad5 vaccine, ART intensification)                     | <a href="#">NCT00976404</a>                           | Vical/GenVec/CHERUB/NIH Vaccine Research Center/ORVACS                 | Phase II   | <a href="#">Lancet HIV. 2015 Mar;2(3):e82-91</a><br>CROI 2014, <a href="#">Poster abstract 422</a>   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

## Research Toward a Cure April 14, 2022

Table 3. Completed Studies (Cont.)

| Trial   | Trial Registry Identifier(s)  | Manufacturer/ Sponsor(s)   | Phase      | Published/Presented Data   |
|---|---|--|------------|--|
| <b>COMBINATIONS (Cont.)</b>   |   |  |            |  |
| <b>disulfiram + vorinostat</b>  | <a href="#">NCT03198559</a><br>(suspended due to neurotoxicity)           | The Peter Doherty Institute for Infection and Immunity                             | Phase I/II | <a href="#">AIDS. 2021 Sep 29.</a><br>CROI 2019, <a href="#">Abstract 401</a>  |
| <b>GTU-MultiHIV B-clade + MVA HIV-B +/- vedolizumab</b> (DNA + viral vector vaccines +/- anti- $\alpha_4\beta_7$ integrin antibody) | <a href="#">NCT02972450</a>   | Inserm-ANRS  | Phase I/II | Terminated due to the bankruptcy of FITBiotech   |
| <b>Vacc-4x</b> (peptide-based therapeutic vaccine) + <b>romidepsin</b>  | <a href="#">NCT02092116</a>   | Bionor Immuno AS/Celgene   | Phase I/II | CROI 2019, <a href="#">Abstract 397</a><br><a href="#">Lancet HIV 2016, July 7, 2016</a>   |
| <b>Vacc-4x + lenalidomide</b>   | <a href="#">NCT01704781</a>   | Bionor Immuno AS   | Phase I/II | IAS 2015 Towards an HIV Cure Symposium, <a href="#">Poster Abstract PE61</a>   |
| <b>vorinostat + hydroxychloroquine + maraviroc (VHM)</b>  | <a href="#">NCT02475915</a><br><a href="#">NCT02470351</a> (CNS substudy) | South East Asia Research Collaboration with Hawaii                                 | Phase I/II | <a href="#">J Virus Erad. 2020 (6) 100004</a><br>AIDS 2016, <a href="#">Abstract TUAX0101LB</a>  |
| Adoptive transfer of <b>haploidentical NK cells</b> and <b>N-803</b>  | <a href="#">NCT03899480</a>   | University of Minnesota - Clinical and Translational Science Institute             | Phase I    | N/A  |
| <b>AGS-004 + vorinostat</b>   | <a href="#">NCT02707900</a>   | NIAID  | Phase I    | <a href="#">Sci Rep. 2020 Mar 20;10(1):5134.</a><br>IAS 2019, <a href="#">Poster abstract MOPEB272</a>   |
| <b>chemotherapy + maraviroc</b> in people with non-Hodgkin lymphoma   | <a href="#">NCT02486510</a>   | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Phase I    | Terminated due to futility criteria  |
| <b>Chidamide + CAR-T or TCR-T cell therapy</b>  | <a href="#">NCT03980691</a>   | Guangzhou 8th People's Hospital  | Phase I    | N/A  |
| <b>DCV3</b> (dendritic cell-based vaccine pulsed with autologous inactivated HIV) + pegylated interferon                            | <a href="#">NCT02767193</a>   | Judit Pich Martínez, Fundació Clínic per la Recerca Biomèdica                      | Phase I    | <a href="#">Front Immunol. 2021 Nov 11;12:767370.</a><br>CROI 2020, <a href="#">Abstract 282</a><br><a href="#">J Infect Dis. 2020 Apr 27;221(10):1740-1742.</a> |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

Table 3. Completed Studies (Cont.)

| Trial  | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)   | Phase      | Published/Presented Data   |
|--|------------------------------|--|------------|--|
| <b>COMBINATIONS (Cont.)</b>                        |                              |  |            |  |
| MVA-B (viral vector vaccine) +/- disulfiram        | <a href="#">NCT01571466</a>  | Hospital Clinic of Barcelona/HIVACAT                                   | Phase I    | <a href="#">PLoS One. 2015 Nov 6;10(11):e0141456.</a><br><a href="#">J Antimicrob Chemother. 2015 Feb 26. pii: dkv046.</a>   |
| MVA.HIVconsv + romidepsin                          | <a href="#">NCT02616874</a>  | IrsiCaixa  | Phase I    | <a href="#">Microbiome. 2022 Apr 11;10(1):59.</a><br><a href="#">EBioMedicine. 2022 Mar 21;78:103956.</a><br><a href="#">AIDS. 2021 Nov 3</a><br><a href="#">J Antimicrob Chemother. 2020 Dec 22;dkaa523.</a><br><a href="#">Front Immunol. 2020 May 6;11:823.</a><br>CROI 2019, <a href="#">Abstract 438</a><br>CROI 2017, <a href="#">Abstract 119LB</a> , <a href="#">Webcast</a> |
| VRC07-523LS + vorinostat                           | <a href="#">NCT03803605</a>  | University of North Carolina, Chapel Hill                              | Phase I    | <a href="#">J Infect Dis. 2021 Sep 25;jiab487.</a><br>IAS 2021, <a href="#">Abstract OALA01LB03 (video)</a>  |
| <b>CYTOKINES</b>                                   |                              |  |            |  |
| interleukin-2 (IL-2)                               | <a href="#">NCT03308786</a>  | Case Western Reserve University  | Phase II   | N/A  |
| N-803  | <a href="#">NCT02191098</a>  | University of Minnesota - Clinical and Translational Science Institute | Phase I    | <a href="#">Nat Med. 2022 Jan 31.</a><br>CROI 2018, <a href="#">Poster abstract 356</a>  |
| <b>DUAL-AFFINITY RE-TARGETING (DART) MOLECULES</b> |                              |  |            |  |
| MGD014   | <a href="#">NCT03570918</a>  | MacroGenics  | Phase I    | N/A  |
| <b>GENE THERAPIES</b>                              |                              |  |            |  |
| OZ1  | <a href="#">NCT00074997</a>  | Janssen-Cilag Pty Ltd  | Phase II   | <a href="#">Nat Med. 2009 Mar; 15(3): 285–292.</a>   |
| Cal-1: Dual anti-HIV gene transfer construct       | <a href="#">NCT01734850</a>  | Calimmune  | Phase I/II | <a href="#">Results posted in clinicaltrials.gov</a>   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)



# Research Toward a Cure April 14, 2022

**Table 3. Completed Studies (Cont.)**

| Trial   | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                       | Phase      | Published/Presented Data   |
|---|------------------------------|--|------------|--|
| <b>GENE THERAPIES (Cont.)</b>   |                              |  |            |  |
| <b>SB-728mR-T</b> (autologous CD4 T cells genetically modified at the CCR5 gene) + cyclophosphamide | <a href="#">NCT02225665</a>  | Sangamo BioSciences                            | Phase I/II | N/A  |
| <b>SB-728-T</b> + cyclophosphamide  | <a href="#">NCT01543152</a>  | Sangamo BioSciences                            | Phase I/II | <a href="#">bioRxiv 2021.02.28.433290</a><br>CROI 2016, <a href="#">Poster abstract 358LB</a><br>CROI 2015, <a href="#">Poster abstract 434</a><br>CROI 2014, <a href="#">Abstract 141</a> , <a href="#">Webcast</a> |
| <b>SB-728-T</b>   | <a href="#">NCT01252641</a>  | Sangamo BioSciences                            | Phase I/II | N/A  |
| <b>VRX496</b> (gene-modified autologous CD4 T cells)  | <a href="#">NCT00295477</a>  | University of Pennsylvania                     | Phase I/II | <a href="#">Blood. 2013 Feb 28; 121(9): 1524–1533</a>  |
| <b>C34-CXCR4</b> (autologous CD4 T cells gene-modified to express HIV-inhibiting C34 peptide)       | <a href="#">NCT03020524</a>  | University of Pennsylvania                     | Phase I    | N/A  |
| <b>HGTV43</b>   | No clinicaltrials.gov entry  | Enzo Biochem                                   | Phase I    | AIDS 2006, <a href="#">Abstract MOPDA06</a>  |
| <b>MazF-T</b> (redirected MazF-CD4 autologous T cells)  | <a href="#">NCT01787994</a>  | Takara Bio/University of Pennsylvania          | Phase I    | <a href="#">Mol Ther 2020 Nov 10</a><br>CROI 2015, <a href="#">Poster abstract 402</a>   |
| Redirected high affinity Gag-specific T cells   | <a href="#">NCT00991224</a>  | University of Pennsylvania/Adaptimmune         | Phase I    | Study closed (safety): <a href="#">Mol Ther. 2015 Jul; 23(7): 1149–1159.</a>   |
| <b>SB-728mR-T</b> + cyclophosphamide  | <a href="#">NCT02388594</a>  | University of Pennsylvania                     | Phase I    | <a href="#">J Clin Invest. 2021.</a><br>CROI 2019, <a href="#">Abstract 25</a> , <a href="#">Webcast</a>   |
| <b>SB-728-T</b>   | <a href="#">NCT01044654</a>  | Sangamo BioSciences                            | Phase I    | <a href="#">bioRxiv 2021.02.28.433290</a><br>ICAAC 2014, Abstract H-643; ICAAC 2013, Abstract H-1464c  |
| <b>SB-728-T</b>   | <a href="#">NCT00842634</a>  | Sangamo Biosciences/University of Pennsylvania | Phase I    | <a href="#">N Engl J Med. 2014 Mar 6;370(10):901–10</a>  |
| shRNA-modified CD34+ cells  | <a href="#">NCT03517631</a>  | Shanghai Public Health Clinical Center         | Phase I    | N/A  |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

| Trial   | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)  | Phase      | Published/Presented Data  |
|---|------------------------------|---|------------|---|
| <b>GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS</b>  |                              |   |            |   |
| CRISPR CCR5 modified CD34+ cells  | <a href="#">NCT03164135</a>  | 307 Hospital of PLA (Affiliated Hospital of Academy to Military Medical Sciences) | Not listed | <a href="#">N Engl J Med. 2019 Sep 11</a>   |
| Stem cells gene-modified with M87o vector encoding HIV-inhibiting C46 peptide                     | <a href="#">NCT00858793</a>  | Universitätsklinikum Hamburg-Eppendorf  | Phase I/II | N/A   |
| Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ)                  | <a href="#">NCT00569985</a>  | City of Hope Medical Center   | Phase I    | <a href="#">Sci Transl Med. 2010 Jun 16; 2(36): 36ra43.</a>   |
| <b>HORMONES</b>   |                              |   |            |   |
| <b>somatotropin</b> (human growth hormone)  | <a href="#">NCT03091374</a>  | McGill University Health Center   | Phase II   | CROI 2021, <a href="#">Abstract 298</a> , <a href="#">Webcast</a>   |
| <b>IMAGING STUDIES</b>  |                              |   |            |   |
| 123I radiolabeled 3BNC117   | <a href="#">NCT03468582</a>  | University of Lausanne Hospitals  | Phase I    | N/A   |
| Radiolabeled 3BNC117 + Copper-64 radio isotope followed by MRI/PET scanning to detect HIV in vivo | <a href="#">NCT03063788</a>  | Bayside Health  | Phase I    | <a href="#">EBioMedicine. 2021 Feb 25;65:103252.</a><br>AIDS 2020, <a href="#">Abstract PEA0060</a>   |
| <b>IMMUNE CHECKPOINT INHIBITORS</b>   |                              |   |            |   |
| <b>cemiplimab</b> (anti-PD-1 antibody)  | <a href="#">NCT03787095</a>  | NIAID   | Phase I/II | <a href="#">J Acquir Immune Defic Syndr. 2021 Aug 15;87(5):e234-e236.</a><br>Pre-CROI Community HIV Cure Research Workshop 2020 ( <a href="#">slides</a> , <a href="#">video</a> )<br><a href="#">ACTG announcement</a> |
| <b>BMS-936559</b> (anti-PD-L1 antibody)   | <a href="#">NCT02028403</a>  | National Institute of Allergy and Infectious Diseases (NIAID)                     | Phase I    | <a href="#">J Infect Dis. 2017 Jun 1;215(11):1725-1733</a><br>CROI 2016, <a href="#">Abstract 25</a> , <a href="#">Webcast</a>  |
| <b>ipilimumab</b> (anti-CTLA-4 antibody)  | <a href="#">NCT03407105</a>  | Medarex   | Phase I    | <a href="#">PLoS One. 2018 Jun 7;13(6):e0198158</a>   |
| <b>IRON CHELATORS</b>   |                              |   |            |   |
| <b>deferiprone</b>  | <a href="#">NCT02456558</a>  | ApoPharma   | Phase I    | N/A   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

## Research Toward a Cure April 14, 2022

Table 3. Completed Studies (Cont.)

| Trial  | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)   | Phase         | Published/Presented Data  |
|--|------------------------------|--|---------------|---|
| <b>JANUS KINASE INHIBITORS</b>                           |                              |  |               |   |
| <b>ruxolitinib</b>                                       | <a href="#">NCT02475655</a>  | NIAID  | Phase II      | <a href="#">J Clin Pharmacol. 2021 Jun 24.</a><br><a href="#">Clin Infect Dis. 2021 CROI 2019, Abstract 37, Webcast</a>   |
| <b>LATENCY-REVERSING AGENTS</b>                          |                              |  |               |   |
| <b>disulfiram</b> (acetaldehyde dehydrogenase inhibitor) | <a href="#">NCT01286259</a>  | University of California, San Francisco/ Johns Hopkins University/amfAR                                    | Not specified | <a href="#">Clin Infect Dis. 2014 58 (6): 883–90</a>  |
| <b>Chidamide</b>   | <a href="#">NCT02902185</a>  | Tang-Du Hospital   | Phase II/III  | N/A   |
| <b>vorinostat</b> (HDAC inhibitor)                       | <a href="#">NCT01365065</a>  | Bayside Health/Merck   | Phase II      | <a href="#">PLoS Pathog. 2014;10(10):e1004473</a>   |
| <b>valproic acid</b> (HDAC inhibitor)                    | <a href="#">NCT00289952</a>  | McGill University/Canadian Foundation for AIDS Research/CIHR Canadian HIV Trials Network                   | Phase II      | <a href="#">HIV Med. 2012 May;13(5):291–6</a>   |
| <b>valproic acid</b>                                     | <a href="#">NCT00614458</a>  | University of North Carolina at Chapel Hill/NIAID/Abbott/Merck Sharp & Dohme                               | Phase II      | <a href="#">PLoS One. 2010 5(2): e9390</a>  |
| <b>Chidamide</b> (HDAC inhibitor)                        | <a href="#">NCT02513901</a>  | Tang-Du Hospital   | Phase I/II    | <a href="#">HIV Med. 2020 Dec;21(11):747-757.</a><br>AIDS 2018, Abstract WEAA0101 ( <a href="#">slides</a> , <a href="#">video</a> )                              |
| <b>disulfiram</b>  | <a href="#">NCT01944371</a>  | University of California, San Francisco/Monash University/amfAR  | Phase I/II    | CROI 2015, <a href="#">Poster abstract 428LB</a>  |
| <b>panobinostat</b> (HDAC inhibitor)                     | <a href="#">NCT01680094</a>  | University of Aarhus/Massachusetts General Hospital/Monash University/Karolinska Institutet/Novartis/amfAR | Phase I/II    | CROI 2015, <a href="#">Abstract 109, Webcast</a><br><a href="#">The Lancet HIV. 2014 Oct; 1(1): e13–e21</a>   |
| <b>romidepsin</b> (HDAC inhibitor)                       | <a href="#">NCT01933594</a>  | AIDS Clinical Trials Group/NIAID/Gilead  | Phase I/II    | <a href="#">The Journal of Infectious Diseases, jiaa777</a><br>CROI 2019, <a href="#">Abstract 26, Webcast</a><br>CROI 2018, <a href="#">Abstract 72, Webcast</a> |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

## Research Toward a Cure April 14, 2022

**Table 3. Completed Studies (Cont.)**

| Trial  | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)   | Phase      | Published/Presented Data   |
|--|------------------------------|--|------------|--|
| <b>LATENCY-REVERSING AGENTS (Cont.)</b>  |                              |  |            |  |
| <b>valproic acid + pyrimethamine</b>   | <a href="#">NCT03525730</a>  | Erasmus Medical Center   | Phase I/II | N/A  |
| <b>vorinostat</b>  | <a href="#">NCT01319383</a>  | University of North Carolina at Chapel Hill/NIAID/Merck.                           | Phase I/II | <a href="#">J Clin Invest. 2017 Aug 1;127(8):3126-3135.</a><br><a href="#">J Infect Dis. 2014 Sep 1;210(5):728-35</a><br><a href="#">Nature. 2012 Jul 25;487(7408):482-5</a> |
| <b>bryostatin 1 (PKC agonist)</b>  | <a href="#">NCT02269605</a>  | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Phase I    | <a href="#">AIDS. 2016 Jun 1;30(9):1385-92.</a>  |
| <b>mTOR INHIBITORS</b>   |                              |  |            |  |
| Impact of <b>Everolimus</b> on HIV persistence post kidney or liver transplant | <a href="#">NCT02429869</a>  | UCSF   | Phase IV   | <a href="#">Am J Transplant. 2020 Aug 11</a>   |
| <b>Sirolimus</b>   | <a href="#">NCT02440789</a>  | ACTG   | Phase I/II | CROI 2019, <a href="#">Abstract 131</a> , <a href="#">Webcast</a>  |
| <b>metformin</b>   | <a href="#">NCT02659306</a>  | McGill University Health Center  | Phase I    | <a href="#">EBioMedicine 65 (2021) 103270</a><br>CROI 2020, <a href="#">Poster abstract 229</a><br>CROI 2019, <a href="#">Poster abstract 301</a>                            |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure April 14, 2022

**Table 3. Completed Studies (Cont.)**

| Trial  | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)   | Phase | Published/Presented Data   |
|--|------------------------------|----------------------------|-------|--|
| <b>OBSERVATIONAL STUDIES</b>   |                              |                            |       |  |
| <b>ACTG A5321:</b> Decay of HIV-1 reservoirs in subjects on long-term antiretroviral therapy: The ACTG HIV reservoirs cohort (AHRC) study                            | N/A                          | AIDS Clinical Trials Group | N/A   | <a href="#">Front Cell Infect Microbiol. 2022 Feb 10:12:757846.</a><br><a href="#">J Infect Dis. 2022:jjac030 medRxiv 2021.11.08.21266096</a><br>CROI 2021, <a href="#">Abstract 241</a> , <a href="#">Webcast</a><br>HIV Persistence 2019, Abstracts OP 4.6, 5.6 & PP 4.4 (see <a href="#">abstract book</a> )<br>CROI 2018, <a href="#">Abstract 119</a> , <a href="#">Webcast</a><br><a href="#">Abstract 403LB</a><br><a href="#">PLoS Pathog. 2017 Apr; 13(4): e1006285</a> |
| <b>ANRS EP 44:</b> Residual replication of HIV-1 in the gut associated lymphoid tissue (GALT)  | <a href="#">NCT01038401</a>  | Inserm-ANRS                | N/A   | N/A  |
| <b>ANRS EP63:</b> A chronological study of the formation of HIV cellular reservoirs through the expression of surface markers on CD4+ T lymphocytes, including CD32a | <a href="#">NCT03298360</a>  | Inserm-ANRS                | N/A   | N/A  |
| <b>APACHE:</b> Monitored antiretroviral pause in chronically infected HIV+ individuals with long-lasting suppressed viremia  | <a href="#">NCT03198325</a>  | Ospedale San Raffaele      | N/A   | <a href="#">PLoS One. 2022 Mar 15:17(3):e0265348.</a><br><a href="#">Viruses. 2021 Jul 19:13(7):1403.</a><br><a href="#">AIDS: May 14, 2021</a><br><a href="#">J Antimicrob Chemother. 2021 Mar 7:dkab060.</a><br><a href="#">J Antimicrob Chemother. 2020 Jun 15:dkaa231.</a><br>HIV Persistence 2019, Abstract PP 5.7.10 (see <a href="#">abstract book</a> )<br><a href="#">J Antimicrob Chemother. 2019 April 23. pii: dkz138</a>  |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

## Research Toward a Cure April 14, 2022

Table 3. Completed Studies (Cont.)

| Trial   | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)  | Phase | Published/ Presented Data   |
|---|------------------------------|---|-------|---|
| <b>OBSERVATIONAL STUDIES (Cont.)</b>  |                              |   |       |   |
| Biomarkers to predict time to plasma HIV RNA rebound (ACTG A5345)   | <a href="#">NCT03001128</a>  | AIDS Clinical Trials Group  | N/A   | <a href="#">AIDS Res Hum Retroviruses. 2022 Mar 24.</a><br>CROI 2022, <a href="#">Abstract 379</a><br><a href="#">Clin Infect Dis. 2021 Jun 12;ciab541.</a><br>CROI 2021, <a href="#">Abstract 311</a> , <a href="#">Webcast</a><br>AIDS 2020, <a href="#">Abstract PDB0102</a>                         |
| <b>CHERUB 003</b><br>(prospective HIV chemotherapy cohort study)  | <a href="#">NCT01902693</a>  | Imperial College London/CHERUB  | N/A   | N/A   |
| <b>CLEAC:</b> Comparison of late versus early antiretroviral therapy in HIV-infected children               | <a href="#">NCT02674867</a>  | Inserm-ANRS   | N/A   | <a href="#">Front Immunol. 2021 Apr 22;12:662894.</a><br><a href="#">Clin Infect Dis. ciaa1931</a><br>AIDS 2018, <a href="#">Abstract WEAB0208LB (slides)</a>   |
| Effects of dolutegravir based regimen on HIV-1 reservoir and immune activation                              | <a href="#">NCT02557997</a>  | University Hospital, Strasbourg, France   | N/A   | <a href="#">J Antimicrob Chemother. 2017 Dec 13.</a>  |
| <b>EPIC4:</b> Early Pediatric Initiation: Canada Child cure Cohort Study                                    | <a href="#">CTN S 281</a>    | Canadian Institutes of Health Research (CIHR)/Canadian Foundation for AIDS Research (CANFAR)/International AIDS Society (IAS) | N/A   | <a href="#">AIDS: December 02, 2019</a><br><a href="#">Clin Infect Dis. 2019 Mar 28. pii: ciz251</a><br>2015 IAS Towards an HIV Cure Symposium, <a href="#">Abstract PE69LB</a><br>AIDS 2014, <a href="#">Abstract TUAB0206LB (video)</a><br><a href="#">Clin Infect Dis. (2014) 59 (7): 1012-1019.</a> |
| <b>EURECA:</b> Exploratory study of cellular reservoirs in blood  | <a href="#">NCT02858414</a>  | Centre Hospitalier Universitaire de Besancon  | N/A   | <a href="#">Viruses. 2018 Apr 13;10(4).</a>   |
| <b>FXReservoir:</b> Study of the effects of farnesoid X receptor ligands on reactivation of latent provirus | <a href="#">NCT03618862</a>  | Hospices Civils de Lyon   | N/A   | N/A   |
| Genotyping FcγRs genes  | <a href="#">NCT03130296</a>  | University Hospital, Strasbourg, France   | N/A   | <a href="#">Genes Immun. 2020 Aug;21(4):263-268</a>   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

| Trial   | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                  | Phase | Published/Presented Data  |
|---|------------------------------|---|-------|---|
| <b>OBSERVATIONAL STUDIES (Cont.)</b>  |                              |   |       |   |
| <b>HCURE:</b> Analysis of the impact of HCV direct antiviral agents (DAA) on antiviral Immunity and HIV DNA reservoir in coinfecting HIV-HCV patients | <a href="#">NCT03244371</a>  | Assistance Publique Hopitaux De Marseille | N/A   | N/A   |
| <b>HIV-PRADA:</b> HIV persistence in lymph node and peripheral blood  | <a href="#">NCT03426189</a>  | University of Melbourne                   | N/A   | CROI 2021, <a href="#">Abstract 301</a> , <a href="#">Webcast</a>   |
| HIV resistance and treatment strategies   | <a href="#">NCT00581802</a>  | NIAID                                     | N/A   | N/A   |
| <b>HIV-STAR:</b> HIV sequencing after treatment interruption to identify the clinically relevant anatomical reservoir                                 | <a href="#">NCT02641756</a>  | University Hospital, Ghent                | N/A   | IAS 2021, <a href="#">Abstract PEA036 (poster, video)</a><br><a href="#">J Virus Erad. 2021 Jan 23;7(1):100029.</a><br>CROI 2020, <a href="#">Abstract 324</a><br><a href="#">Cell Host Microbe. 2019 Sep 11;26(3):347-358.e7.</a><br>AIDS 2018, Abstract <a href="#">WEAA0201 (slides, video)</a> , poster abstract <a href="#">THPEB096</a> |
| <b>HSCT-HIV:</b> Allogeneic hematopoietic stem cell transplantation in HIV+ patients  | <a href="#">NCT02732457</a>  | Kirby Institute                           | N/A   | Terminated by Protocol Steering Committee   |
| <b>ImmunoCo27:</b> Co-adaptation between HIV and CD8 cellular immunity  | <a href="#">NCT02886416</a>  | Inserm-ANRS                               | N/A   | N/A   |
| <b>IMPAACT 2015:</b> Evaluation of the HIV-1 reservoir in the CNS of perinatally-infected youth and young adults with cognitive impairment            | <a href="#">NCT03416790</a>  | IMPAACT                                   | N/A   | N/A   |
| Impact of ART adherence on HIV persistence and inflammation   | <a href="#">NCT02797093</a>  | University of Colorado, Denver            | N/A   | N/A   |
| Impact of a short-term ATI and re-initiation of antiretroviral therapy on immunologic and virologic parameters in HIV+ individuals                    | <a href="#">NCT03225118</a>  | NIAID                                     | N/A   | <a href="#">J Infect Dis. 2020 May 22;jiaa270.</a>  |
| In vitro autologous vaccine development to activate HIV reservoirs  | UK CPMS17532                 | Imperial College London/amfAR             | N/A   | N/A   |
| <b>ISALA:</b> Analytical treatment interruption in HIV positive patients  | <a href="#">NCT02590354</a>  | Institute of Tropical Medicine, Belgium   | N/A   | <a href="#">J Int AIDS Soc. 2020 Feb;23(2):e25453.</a><br>CROI 2019, <a href="#">Poster abstract 389</a> , <a href="#">Webcast</a>  |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

## Research Toward a Cure April 14, 2022

Table 3. Completed Studies (Cont.)

| Trial  | Trial Registry Identifier(s)  | Manufacturer/ Sponsor(s)  | Phase | Published/Presented Data   |
|--|---|---|-------|--|
| <b>OBSERVATIONAL STUDIES (Cont.)</b>   |   |   |       |  |
| <b>LoViReT:</b> Low viral reservoir treated patients   | <a href="#">NCT02972931</a>   | IrsiCaixa   | N/A   | <a href="#">J Intern Med. 2022 Mar 28.</a><br><a href="#">EBioMedicine. 2020 Jun 21;57:102830.</a><br>CROI 2020, <a href="#">Abstract 374</a><br>HIV Persistence Workshop 2019, Abstract OP 3.5 (see <a href="#">abstract book</a> )<br>HIV Persistence Workshop 2017, <a href="#">Abstract OP 8.6</a> |
| <b>MUCOVIR:</b> Exploration of HIV reservoirs  | <a href="#">NCT01019044</a>   | Objectif Recherche Vaccins SIDA   | N/A   | <a href="#">JAIDS. 2013 Mar 1;62(3):255–9</a>  |
| <b>PembroHIV:</b> Treatment with immunological checkpoint inhibitors of HIV+ individuals with cancer | <a href="#">NCT03767465</a>   | IrsiCaixa   | N/A   | HIV Persistence Workshop 2019, Abstract PP 4.2 (see <a href="#">abstract book</a> )  |
| <b>PITCH:</b> Prospective interruption of therapy towards a cure for HIV pilot study                 | <a href="#">NHS Health Research Authority approval</a> (not entered into any online registry) | University of Oxford  | N/A   | CROI 2022, <a href="#">Abstract 266</a><br>BHIVA Digital Conference, Nov 22–24, 2020, <a href="#">Abstract P22</a>   |
| Quantitative measurement and correlates of the latent HIV reservoir in virally suppressed Ugandans   | <a href="#">NCT02154035</a>   | NIAID   | N/A   | <a href="#">JCI Insight. 2020 Jun 16;139287.</a><br>CROI 2020, <a href="#">Abstract 385</a><br>Persistence Workshop 2019, <a href="#">Abstract OP 7.4</a><br><a href="#">Clin Infect Dis. 2017 Oct 15;65(8):1308-1315.</a>   |
| Role of anti-Tat immunity on disease progression in HIV+ asymptomatic adults                         | <a href="#">NCT01029548</a>   | National HIV/AIDS Research Center (CNAIDS), Istituto Superiore di Sanità, Rome, Italy | N/A   | <a href="#">Retrovirology. 2014 Jun 24;11:49.</a>  |
| Role of anti-Tat immunity on disease progression in HIV+ cART-treated adults                         | <a href="#">NCT01024556</a>   | CNAIDS, Istituto Superiore di Sanità, Rome, Italy                                     | N/A   | <a href="#">EBioMedicine 00 (2021) 103306</a>  |
| Seroprevalence of anti-Tat antibodies in HIV+ South African patients                                 | <a href="#">NCT01359800</a>   | CNAIDS, Istituto Superiore di Sanità, Rome, Italy                                     | N/A   | N/A  |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)



# Research Toward a Cure April 14, 2022

**Table 3. Completed Studies (Cont.)**

| Trial  | Trial Registry Identifier(s)                          | Manufacturer/ Sponsor(s)  | Phase    | Published/Presented Data   |
|--|---|---|----------|--|
| <b>OBSERVATIONAL STUDIES (Cont.)</b>   |   |   |          |  |
| Size of the HIV-1 reservoir and ongoing replication in defined cohorts   | UK CPMS16004  | University College London/amfAR   | N/A      | N/A  |
| Specimen repository for HIV immunopathogenesis   | <a href="#">NCT03579381</a>                           | AIDS Healthcare Foundation  | N/A      | N/A  |
| Tissue drug levels of HIV medications  | <a href="#">NCT01490346</a>                           | University of Minnesota – Clinical and Translational Science Institute/NIAID  | N/A      | <a href="#">Proc Natl Acad Sci USA. 2014 Feb 11;111(6):2307-12.</a>  |
| <b>ULTRASTOP</b> (Towards HIV Functional Cure)<br><b>ERAMUNE-03</b> (antiretroviral treatment interruption)                                  | <a href="#">NCT01876862</a>                           | Objectif Recherche VACcin Sida (ORVACS)/Fondation Bettencourt Schueller   | N/A      | <a href="#">AIDS, Published Ahead-of-Print, January 4, 2016</a>  |
| <b>VIRECT</b> : Impact of pre-ART CD4 T cell level on the rectal reservoir in long-term HIV-1 treated men                                    | <a href="#">NCT02526940</a>                           | Centre Hospitalier Universitaire de Saint Etienne   | N/A      | N/A  |
| <b>PROTEASOME INHIBITORS</b>   |   |   |          |  |
| <b>ixazomib</b>  | <a href="#">NCT02946047</a><br>(closed to enrollment) | Mayo Clinic   | Phase I  | <a href="#">EClinicalMedicine 2021 Nov 29;42:101225.</a>   |
| <b>STEM CELL TRANSPLANTATION</b>   |   |   |          |  |
| <b>HIVECT</b> : HIV eradication through cord-blood transplantation   | <a href="#">NCT02923076</a>                           | Puerta de Hierro University Hospital  | N/A      | N/A  |
| <b>BMT CTN 0903</b> : Allogeneic transplant in individuals with chemotherapy-sensitive hematologic malignancies and coincident HIV infection | <a href="#">NCT01410344</a>                           | National Heart, Lung, & Blood Institute/National Cancer Institute/Blood & Marrow Transplant Clinical Trials Network | Phase II | <a href="#">Biol Blood Marrow Transplant. 2019 Jul 4. pii: S1083-8791(19)30417-3. J Clin Oncol. 35, no. 15 suppl (May 2017) 7006-7006.</a> |
| HLA-mismatched unrelated donor bone marrow transplantation   | <a href="#">NCT02793544</a>                           | Center for International Blood and Marrow Transplant Research   | Phase II | <a href="#">HRSA Advisory Council on Blood Stem Cell Transplantation, September 25, 2020</a>   |
| Immune response after stem cell transplant in HIV-positive patients with hematologic cancer  | <a href="#">NCT00968630</a>                           | Fred Hutchinson Cancer Research Center  | Phase II | N/A  |
| Optimized antiretroviral therapy during allogeneic hematopoietic stem cell transplantation in HIV-1 individuals                              | <a href="#">NCT01836068</a>                           | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins  | Phase I  | <a href="#">JAIDS 2021 Nov 8. AIDS Res Hum Retroviruses. 2021 Jun 9. Lancet HIV. 2020 Jul 7: S2352-3018(20)30073-4.</a>                    |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

| Trial  | Trial Registry Identifier(s)  | Manufacturer/ Sponsor(s)                          | Phase     | Published/Presented Data   |
|--|---|---|-----------|--|
| <b>THERAPEUTIC VACCINES</b>  |   |   |           |  |
| <b>AGS-004</b> (personalized therapeutic vaccine utilizing patient-derived dendritic cells and HIV antigens) | <a href="#">NCT00672191</a>   | Argos Therapeutics                                | Phase IIb | <a href="#">J Acquir Immune Defic Syndr. 2016 May 1;72(1):31-8</a>   |
| <b>AGS-004</b>   | <a href="#">NCT01069809</a>   | Argos Therapeutics                                | Phase IIb | <a href="#">AIDS Res Hum Retroviruses. 2018 Jan;34(1):111-122</a><br><a href="#">IAS 2015 Towards an HIV Cure Symposium, Combination Therapy Trials Roundtable</a><br><a href="#">CROI 2014, Poster abstract 344</a> |
| <b>iHIVARNA-01</b> (TriMix & HIV antigen naked messenger RNA)  | <a href="#">NCT02888756</a>   | Rob Gruters, Erasmus Medical Center               | Phase IIa | <a href="#">Vaccines (Basel). 2019 Dec 6;7(4). pii: E209.</a>  |
| <b>DermaVir</b> (topically applied DNA vaccine)  | <a href="#">NCT00711230</a>   | Genetic Immunity                                  | Phase II  | N/A  |
| <b>DermaVir</b>  | <a href="#">NCT00918840</a>   | Genetic Immunity                                  | Phase II  | N/A  |
| <b>GSK Biologicals HIV Vaccine 732462</b> (p24-RT-Nef-p17 fusion protein vaccine)                            | <a href="#">NCT01218113</a>   | GlaxoSmithKline                                   | Phase II  | <a href="#">Medicine (Baltimore). 2016 Feb;95(6):e2673</a>   |
| <b>GTU-multiHIV + LIPO-5</b> (DNA + lipopeptide vaccines)  | <a href="#">NCT01492985</a>   | Inserm-ANRS                                       | Phase II  | <a href="#">J Infect Dis. 2019 Jul 2;220:S5-S6</a><br><a href="#">AIDS. 2018 Oct 15 HIVR4P 2016, Abstract P27.09</a>   |
| <b>Tat protein vaccine</b>   | <a href="#">NCT01513135</a><br><a href="#">NCT02712489</a> (extended follow-up study) | CNAIDS, Istituto Superiore di Sanità, Rome, Italy | Phase II  | <a href="#">Retrovirology. 2016 Jun 9;13(1):34</a>   |
| <b>Tat protein vaccine</b>   | <a href="#">NCT00751595</a><br><a href="#">NCT02118168</a> (extended follow-up study) | Barbara Ensoli, MD, Istituto Superiore di Sanità  | Phase II  | <a href="#">Front. Immunol. February 13, 2019</a><br><a href="#">Retrovirology. 2015 Apr 29;12(1):33</a><br><a href="#">PLoS One. 2010 Nov 11;5(11):e13540</a>   |
| <b>Vacc-4x</b> (peptide-based vaccine)   | <a href="#">NCT01712256</a>   | Bionor Immuno AS                                  | Phase II  | <a href="#">PLoS One. 2019 Jan 30;14(1):e0210965.</a>  |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

| Trial  | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)  | Phase       | Published/Presented Data  |
|--|------------------------------|---|-------------|---|
| <b>THERAPEUTIC VACCINES (Cont.)</b>                    |                              |   |             |   |
| Vacc-4x  | <a href="#">NCT00659789</a>  | Bionor Immuno AS  | Phase II    | <a href="#">Lancet Infect Dis. 2014 Apr;14(4):291-300</a>   |
| VAC-3S (peptide-based vaccine)                         | <a href="#">NCT02041247</a>  | InnaVirVax  | Phase II    | <a href="#">NPJ Vaccines (2019) 4:1</a><br>IAS 2017, Abstract MOSY0404 ( <a href="#">slides</a> , <a href="#">video</a> )                             |
| VAC-3S   | <a href="#">NCT02390466</a>  | InnaVirVax  | Phase I/IIa | N/A   |
| VAC-3S (peptide-based vaccine)                         | <a href="#">NCT01549119</a>  | InnaVirVax  | Phase I/IIa | IAS 2015 Towards an HIV Cure Symposium, <a href="#">Poster abstract PE67 LB</a><br>30 Years of HIV Science, 2013, <a href="#">Poster abstract 145</a> |
| AGS-004  | <a href="#">NCT02042248</a>  | University of North Carolina at Chapel Hill/Argos Therapeutics/U.S. National Institutes of Health (NIH) | Phase I/II  | N/A   |
| Autologous HIV-1 ApB DC Vaccine                        | <a href="#">NCT00510497</a>  | Sharon Riddler, University of Pittsburgh/NIAID  | Phase I/II  | <a href="#">J Infect Dis. 2016 May 1;213(9):1400-9</a>  |
| Dendritic cells pulsed with chemically inactivated HIV | <a href="#">NCT02766049</a>  | University of Sao Paulo General Hospital  | Phase I/II  | <a href="#">J. Cellular Immunotherapy xx (2016) 1-10</a><br><a href="#">J Int AIDS Soc. 2014 Jan 10;17:18938</a>                                      |
| Dendritic cell vaccine                                 | <a href="#">NCT00833781</a>  | Massachusetts General Hospital  | Phase I/II  | N/A   |
| Dendritic cell vaccine (DCV-2)                         | <a href="#">NCT00402142</a>  | Hospital Clinic of Barcelona  | Phase I/II  | <a href="#">Sci Transl Med. 2013 Jan 2;5(166):166ra2</a>  |
| DermaVir   | <a href="#">NCT00270205</a>  | AIDS Clinical Trials Group  | Phase I/II  | <a href="#">JAIDS. 2013 Dec 1;64(4):351-9</a>   |
| GTU®-MultiHIV B clade vaccine                          | <a href="#">NCT02457689</a>  | Imperial College London   | Phase I/II  | <a href="#">Front Immunol. 2019 Dec 13;10:2911.</a>   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

| Trial  | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)  | Phase      | Published/Presented Data  |
|--|------------------------------|---|------------|---|
| <b>THERAPEUTIC VACCINES (Cont.)</b>  |                              |   |            |   |
| <b>p24CE1/2 + p55<sup>gag</sup> conserved-element DNA vaccines</b>                                   | <a href="#">NCT03560258</a>  | NIAID   | Phase I/II | N/A   |
| <b>PENNVAX-GP or INO-6145 + IL-12 DNA adjuvant (INO-9012) (DNA vaccines)</b>                         | <a href="#">NCT03606213</a>  | Steven Deeks, UCSF  | Phase I/II | CROI 2022, <a href="#">Abstract 284</a>   |
| <b>Tat Oyi (protein-based vaccine)</b>   | <a href="#">NCT01793818</a>  | Biosantech  | Phase I/II | <a href="#">Retrovirology. 2016 Apr 1;13:21</a>   |
| <b>THV01 (lentiviral vector-based therapeutic vaccine)</b>   | <a href="#">NCT02054286</a>  | Theravectys S.A.  | Phase I/II | N/A   |
| <b>TUTI-16 (synthetic HIV-1 Tat epitope vaccine)</b>   | <a href="#">NCT01335191</a>  | Thymon, LLC   | Phase I/II | <a href="#">Hum Vaccin Immunother. 2012 Oct;8(10):1425-30</a>   |
| <b>Vacc-C5 (peptide-based vaccine)</b>   | <a href="#">NCT01627678</a>  | Bionor Immuno AS  | Phase I/II | <a href="#">JAIDS April 2018;77:57</a><br><a href="#">BMC Infect Dis. 2017 Mar 24;17(1):228</a>               |
| <b>Ad26.Mos4.HIV + MVA-Mosaic or clade C gp140 + mosaic gp140 (viral vector vaccines + proteins)</b> | <a href="#">NCT03307915</a>  | Janssen Vaccines & Prevention B.V.  | Phase I    | N/A   |
| <b>Ad26.Mos.HIV + MVA-Mosaic</b>   | <a href="#">NCT02919306</a>  | Janssen Vaccines & Prevention B.V.  | Phase I    | <a href="#">Nat Med March 23, 2020.</a><br>IAS 2019 HIV & HBV Cure Forum, <a href="#">FT5-1 Flash Talk</a>    |
| <b>AFO-18 (peptide-based vaccine)</b>  | <a href="#">NCT01141205</a>  | Statens Serum Institut (SSI)/Ministry of the Interior and Health, Denmark/European and Developing Countries Clinical Trials Partnership (EDCTP) | Phase I    | <a href="#">AIDS Res Hum Retroviruses. 2013 Nov;29(11):1504-12</a>  |
| <b>AFO-18 (peptide-based vaccine)</b>  | <a href="#">NCT01009762</a>  | SSI/Rigshospitalet/Hvidovre University Hosp./Ministry of Interior & Health, Denmark   | Phase I    | <a href="#">Clin Immunol. 2013 Feb;146(2):120-30</a>  |
| <b>AT20-KLH</b>  | MED-AT20-001                 | Medestea Research & Production SpA, Turin   | Phase I    | <a href="#">Vaccine. 2014 Feb 19;32(9):1072-8</a>   |
| <b>ChAdV63.HIVcons + MVA.HIVconsv (viral vector vaccines)</b>  | <a href="#">NCT01712425</a>  | IrsiCaixa/Fundació Lluita contra la SIDA/Hospital Clinic of Barcelona/ HIVACAT/University of Oxford   | Phase I    | <a href="#">EClinicalMedicine. 2019 Jun 5;11:65-80.</a><br>IAS 2015, <a href="#">Poster abstract MOPEA036</a> |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure April 14, 2022

**Table 3. Completed Studies (Cont.)**

| Trial   | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                   | Phase   | Published/Presented Data   |
|---|------------------------------|--|---------|--|
| <b>THERAPEUTIC VACCINES (Cont.)</b>                                   |                              |  |         |  |
| Dendritic cells loaded with HIV-1 lipopeptides                        | <a href="#">NCT00796770</a>  | Baylor Research Institute/ANRS                             | Phase I | <a href="#">PLoS Pathog. 2019 Sep 9;15(9):e1008011.</a><br><a href="#">Retrovirology 2012, 9(Suppl 2):P328</a>   |
| DermaVir  | <a href="#">NCT00712530</a>  | Genetic Immunity   | Phase I | <a href="#">PLoS One. 2012 7(5): e35416</a>  |
| D-GPE DNA + M-GPE MVA (DNA + viral vector vaccines)                   | <a href="#">NCT01881581</a>  | Centers for Disease Control and Prevention, China          | Phase I | N/A  |
| DNA.HTI + MVA.HTI + ChAdOx1.HTI (DNA + viral vector vaccines)         | <a href="#">NCT03204617</a>  | Aelix Therapeutics   | Phase I | CROI 2021, <a href="#">Abstract 161</a> , <a href="#">Webcast</a>  |
| HIVAX (lentiviral vector-based therapeutic vaccine)                   | <a href="#">NCT01428596</a>  | GeneCure Biotechnologies                                   | Phase I | <a href="#">Vaccine. 2020 May 6;S0264-410X(20)30485-0</a><br><a href="#">Vaccine. 2016 Apr 27;34(19):2225-32</a>   |
| HIV-v (peptide-based vaccine)   | <a href="#">NCT01071031</a>  | PepTcell Limited   | Phase I | <a href="#">Vaccine. 2013 Nov 19;31(48):5680-6</a>   |
| iHIVARNA-01 (TriMix & HIV antigen naked messenger RNA)                | <a href="#">NCT02413645</a>  | Biomedical Research Institute August Pi i Sunyer (IDIBAPS) | Phase I | <a href="#">AIDS. 2018 Nov 13;32(17):2533-2545.</a>  |
| JS7 DNA + MVA62B (DNA + viral vector vaccines)                        | <a href="#">NCT01378156</a>  | GeoVax, Inc.   | Phase I | <a href="#">PLoS One. 2016 Oct 6;11(10):e0163164</a>   |
| MAG pDNA vaccine +/- IL-12  | <a href="#">NCT01266616</a>  | NIAID  | Phase I | <a href="#">J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):163-71.</a>  |
| MAG-pDNA + rVSV <sub>IN</sub> HIV-1 Gag (DNA + viral vector vaccines) | <a href="#">NCT01859325</a>  | NIAID/Profectus Biosciences, Inc.                          | Phase I | <a href="#">J. Virology May 20, 2020</a><br>CROI 2019, <a href="#">Poster abstract 392</a> , <a href="#">Webcast</a><br><a href="#">Sci Transl Med. 2017 Dec 6;9(419). pii: eaan8848</a> |
| MVA.HIVconsv  | <a href="#">NCT01024842</a>  | University of Oxford/Medical Research Council              | Phase I | <a href="#">J Int AIDS Soc. 2017 May 19;20(1):21171.</a>   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure April 14, 2022

**Table 3. Completed Studies (Cont.)**

| Trial  | Trial Registry Identifier(s)  | Manufacturer/ Sponsor(s)                            | Phase        | Published/Presented Data   |
|--|---|---|--------------|--|
| <b>THERAPEUTIC VACCINES (Cont.)</b>                                |   |   |              |  |
| <b>PENNVAX-B (Gag, Pol, Env) + electroporation</b>                 | <a href="#">NCT01082692</a>   | Inovio Pharmaceuticals                              | Phase I      | <a href="#">Retrovirology 2012, 9(Suppl 2):P276</a>  |
| <b>PENNVAX-B +/- IL-12 or IL-15</b>                                | <a href="#">NCT00775424</a>   | University of Pennsylvania                          | Phase I      | N/A  |
| Recombinant adenovirus type 5 vaccine                              | <a href="#">NCT02762045</a>   | China CDC   | Phase I      | N/A  |
| <b>rMVA-HIV + rFPV-HIV (viral vector vaccines) in young adults</b> | <a href="#">NCT00107549</a>   | NIAID   | Phase I      | <a href="#">AIDS. 2011 Nov 28; 25(18): 2227-2234</a>   |
| <b>Tat protein vaccine</b>   | <a href="#">NCT00505401</a><br><a href="#">NCT01024595</a> (extended follow-up study) | CNAIDS, Istituto Superiore di Sanità, Rome, Italy   | Phase I      | <a href="#">Rev Recent Clin Trials. 2009 Sep;4(3):195-204</a><br><a href="#">Vaccine. 2009 May 26;27(25-26):3306-12</a><br><a href="#">AIDS. 2008 Oct 18;22(16):2207-9</a>   |
| <b>TOLL-LIKE RECEPTOR AGONISTS</b>                                 |   |   |              |  |
| <b>MGN1703 toll-like receptor 9 (TLR-9) agonist</b>                | <a href="#">NCT02443935</a>   | University of Aarhus                                | Phase Ib/IIa | <a href="#">EBioMedicine. 2019 Jul 9. pii: S2352-3964(19)30440-2.</a><br><a href="#">AIDS. 2019 Mar 29</a><br><a href="#">Clin Infect Dis. 2017 Mar 9</a>  |
| <b>Poly-ICLC (TLR-3 agonist)</b>                                   | <a href="#">NCT02071095</a>   | Nina Bhardwaj, MD/Campbell Foundation/Oncovir, Inc. | Phase I/II   | <a href="#">Front Immunol. 2019 Apr 9;10:725.</a>  |
| <b>vesatolimod (TLR-7 agonist) in ART-treated HIV controllers</b>  | <a href="#">NCT03060447</a>   | Gilead Sciences                                     | Phase Ib     | <a href="#">EACS 2021, Abstract PE2/1</a><br><a href="#">IAS 2021, Abstract OAA0304 (video)</a><br><a href="#">Sci Transl Med. 2021 Jun 23;13(599): eabg3071.</a><br><a href="#">CROI 2020, Abstract 40, Webcast</a> |
| <b>vesatolimod (formerly GS-9620) (TLR-7 agonist)</b>              | <a href="#">NCT02858401</a>   | Gilead Sciences                                     | Phase Ib     | <a href="#">Clinical Infectious Diseases, ciaa1534</a><br><a href="#">IAS 2019, Abstract WEAA0304 (slides)</a>   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

## Research Toward a Cure April 14, 2022

Table 3. Completed Studies (Cont.)

| Trial   | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                         | Phase      | Published/Presented Data  |
|---|------------------------------|--|------------|---|
| <b>TRADITIONAL CHINESE MEDICINE</b>   |                              |  |            |   |
| <b>Triptolide wilfordii</b>   | <a href="#">NCT02219672</a>  | Peking Union Medical College                     | Phase III  | N/A   |
| <b>TREATMENT INTENSIFICATION/EARLY TREATMENT</b>  |                              |  |            |   |
| <b>enfuvirtide</b>  | <a href="#">NCT00051831</a>  | NIAID  | Not listed | <a href="#">J Infect Dis. 2010 Jan 15;201(2):293–6</a>  |
| <b>enfuvirtide</b>  | <a href="#">NCT00334022</a>  | Canadian Immunodeficiency Research Collaborative | Not listed | N/A   |
| <b>New Era Study:</b> Treatment with multi–drug class (MDC) HAART   | <a href="#">NCT00908544</a>  | MUC Research GmbH                                | Not listed | <a href="#">Front Immunol. 2018 Apr 30;9:811</a>  |
| <b>PLUS:</b> Pilot study on the effect of adding raltegravir +/- a second drug on HIV levels in the gut                                   | <a href="#">NCT00884793</a>  | University of California, San Francisco          | Not listed | <a href="#">J Infect Dis. 2010 Nov 15;202(10):1553–61</a><br><a href="#">AIDS. 2010 Oct 23;24(16):2451–60</a>   |
| Anti-HIV medications for people recently infected with HIV  | <a href="#">NCT00106171</a>  | NIAID  | Phase IV   | <a href="#">PLoS One. 2015 10(11):e0143259</a>  |
| <b>DIORR:</b> Dolutegravir impact on residual replication   | <a href="#">NCT02500446</a>  | University of Melbourne                          | Phase IV   | <a href="#">The Lancet HIV, Online First, April 8, 2018</a><br>CROI 2018, <a href="#">Abstract 71, Webcast</a>  |
| <b>DRONE:</b> Impact of starting a dolutegravir-based regimen on HIV-1 proviral DNA reservoir of treatment naïve and experienced patients | <a href="#">NCT02370979</a>  | University Hospital, Strasbourg, France          | Phase IV   | N/A   |
| <b>LEOPARD:</b> Latency and early neonatal provision of antiretroviral drugs clinical trial   | <a href="#">NCT02431975</a>  | Columbia University                              | Phase IV   | <a href="#">Clinical Infectious Diseases, ciab586</a><br><a href="#">J Clin Med. 2021 May 12;10(10):2074.</a><br><a href="#">EClinicalMedicine 18 (2020) 100241</a> |
| <b>P25-INACTION:</b> Implication for strategies of long term control of viral replication in patients with primary HIV infection          | <a href="#">NCT04225325</a>  | Adriano Lazzarin, MD                             | Phase IV   | <a href="#">EACS 2021, Abstract BPD4/3</a>  |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

## Research Toward a Cure April 14, 2022

Table 3. Completed Studies (Cont.)

| Trial  | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)  | Phase        | Published/Presented Data  |
|--|------------------------------|---|--------------|---|
| <b>TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)</b>   |                              |   |              |   |
| <b>ANRS 147 OPTIPRIM:</b> Optimization of primary HIV-1 infection treatment  | <a href="#">NCT01033760</a>  | Inserm-ANRS   | Phase III    | <a href="#">PLoS One. 2013; 8(5): e64219.</a><br><a href="#">PLoS One. 2013; 8(3): e59767</a><br>IAS 2013, <a href="#">Abstract WEAB0101</a><br>IAS Cure Symposium 2013, <a href="#">Presentation</a> |
| <b>maraviroc</b>   | <a href="#">NCT00808002</a>  | Germans Trias i Pujol Hospital  | Phase III    | <a href="#">AIDS. 2014 Jan 28;28(3):325–34</a>  |
| <b>raltegravir + maraviroc</b>   | <a href="#">NCT00935480</a>  | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer                               | Phase III    | N/A   |
| <b>raltegravir</b>   | <a href="#">NCT00554398</a>  | Germans Trias i Pujol Hospital  | Phase III    | <a href="#">Antivir Ther. 2012;17(2):355–64</a>   |
| <b>tenofovir/emtricitabine + dolutegravir or tenofovir/emtricitabine + darunavir/cobicistat</b>                    | <a href="#">NCT02987530</a>  | Inserm/ANRS   | Phase III    | N/A   |
| <b>VIRECURE:</b> Impact of extremely early ART to reduce viral reservoir & induce functional cure of HIV infection | <a href="#">NCT02588820</a>  | David Garcia Cinca, Hospital Clinic of Barcelona  | Phase III    | N/A   |
| Intense acute infection study  | <a href="#">NCT01154673</a>  | University of Toronto   | Phase II/III | N/A   |
| <b>maraviroc</b>   | <a href="#">NCT00795444</a>  | Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal/Pfizer | Phase II     | <a href="#">AIDS. 2013 Aug 24; 27(13):2081-8.</a><br><a href="#">PLoS One. 2011; 6(12):e27864</a>   |
| <b>peginterferon alfa-2a (Pegasys)</b>   | <a href="#">NCT00594880</a>  | Wistar Institute  | Phase II     | <a href="#">EBioMedicine. 2020 Aug 19;59:102945.</a><br><a href="#">J Infect Dis. 2013 Jan 15; 207(2): 213–222</a>  |
| <b>peginterferon alfa-2b</b>   | <a href="#">NCT01935089</a>  | University of Pennsylvania/Wistar Institute   | Phase II     | <a href="#">AIDS Res Hum Retroviruses. 2020 Dec 15.</a><br>CROI 2017, <a href="#">Poster abstract 326</a>   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)



# Research Toward a Cure April 14, 2022

Table 3. Completed Studies (Cont.)

| Trial   | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)   | Phase      | Published/Presented Data   |
|---|------------------------------|--|------------|--|
| <b>TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)</b>  |                              |  |            |  |
| <b>peginterferon alfa-2b</b>  | <a href="#">NCT02227277</a>  | Wistar Institute   | Phase II   | HIV Persistence Workshop 2019, Abstract PP 4.1 (see <a href="#">abstract book</a> )<br>CROI 2019, <a href="#">Abstract 136</a> , <a href="#">Webcast</a> |
| <b>raltegravir</b>  | <a href="#">NCT00520897</a>  | Canadian Immunodeficiency Research Collaborative                                   | Phase II   | <a href="#">AIDS. 2012 Jan 14;26(2):167-74</a>   |
| <b>raltegravir</b>  | <a href="#">NCT00807443</a>  | Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal | Phase II   | <a href="#">AIDS. 2012 Sep 24;26(15):1885-94</a>   |
| Viral suppression after analytic treatment interruption in Thai patients who initiated HAART during acute HIV infection | <a href="#">NCT02614950</a>  | South East Asia Research Collaboration with Hawaii                                 | Phase II   | <a href="#">Nat Med. 2018 Jun 11 [Epub ahead of print]</a><br>CROI 2017, <a href="#">Abstract 124</a> , <a href="#">Webcast</a>                          |
| <b>alpha interferon intensification</b>   | <a href="#">NCT01295515</a>  | NIAID  | Phase I/II | N/A  |
| <b>indinavir + zidovudine + lamivudine + nevirapine</b>   | <a href="#">NCT00001644</a>  | NIAID  | Phase I    | N/A  |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)